SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
(MARK ONE) FORM 10-K
[ X ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934 [FEE REQUIRED]
For the fiscal year ended JULY 31, 1996.
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934 [NO FEE REQUIRED]
For the transition period from to .
Commission File Number 0-5958
SURVIVAL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 52-0898764
(State or other jurisdiction (IRS Employer
of incorporation or organization) Identification No.)
2275 RESEARCH BOULEVARD, ROCKVILLE, MARYLAND 20850
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 301-926-1800
Securities registered pursuant to Section 12(b) of the Act: NONE
Securities registered pursuant to Section 12(g) of the Act: COMMON STOCK,
$.10 PAR VALUE
- ---------------------------------------------------------------------------
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. YES X NO
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [X]
As of September 30, 1996, the aggregate market value of voting stock held by
non-affiliates of the Registrant, based on the average of the high and low sales
prices of such stock reported by the National Association of Securities Dealers,
Inc. on such date, was approximately $12,093,600.
There were 3,097,487 shares of the Registrant's common stock outstanding as of
September 30, 1996.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Survival Technology, Inc. definitive Proxy Statement for the
Annual Meeting of Shareholders for the fiscal year ended July 31, 1996 are
incorporated by reference into Part III of this Form 10-K.
(End of cover page)
2
TABLE OF CONTENTS
PART I
PAGE
----
ITEM 1. BUSINESS
General . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Products and Services . . . . . . . . . . . . . . . . . . . . . 5
Automatic Injectors . . . . . . . . . . . . . . . . . . . . 6
Commercial Products . . . . . . . . . . . . . . . . . . . 6
Military Products . . . . . . . . . . . . . . . . . . . 7
Contract Filling and Packaging . . . . . . . . . . . . . . . 9
CytoGuard . . . . . . . . . . . . . . . . . . . . . . . . . 9
R&D Services. . . . . . . . . . . . . . . . . . . . . . . . 9
Competition.. . . . . . . . . . . . . . . . . . . . . . . . . 10
Backlog and Renegotiation . . . . . . . . . . . . . . . . . . .10
Patents, Trademarks, and Licenses . . . . . . . . . . . . . . 11
Research and Development. . . . . . . . . . . . . . . . . . . .11
Product Liability Insurance . . . . . . . . . . . . . . . . . .12
Government Regulation . . . . . . . . . . . . . . . . . . . . .12
Employees . . . . . . . . . . . . . . . . . . . . . . . . . . .13
ITEM 2. PROPERTIES. . . . . . . . . . . . . . . . . . . . . . . . . . .14
ITEM 3. LEGAL PROCEEDINGS . . . . . . . . . . . . . . . . . . . . . . .14
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF
SECURITY HOLDERS. . . . . . . . . . . . . . . . . . . . . . . .14
EXECUTIVE OFFICERS OF THE REGISTRANT
(UNNUMBERED ITEM) . . . . . . . . . . . . . . . . . . . . . 15
3
TABLE OF CONTENTS
PART II
PAGE
----
ITEM 5. MARKET FOR THE REGISTRANT'S COMMON STOCK
AND RELATED STOCKHOLDER MATTERS . . . . . . . . . . . . . . . .16
ITEM 6. SELECTED FINANCIAL DATA . . . . . . . . . . . . . . . . . . . .17
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS . . . . . . . . . . . . . . . . . . . . . . . . .18
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY
DATA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .25
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE. . . . . . . . . . . . .44
PART III
ITEMS 10
THROUGH 13.
(Incorporated by reference to the definitive
Proxy Statement for the Annual Meeting of
Shareholders for the fiscal year ended
July 31, 1996, which will be filed with the
Securities and Exchange Commission not later
than 120 days after the end of that fiscal
year) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .44
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES,
AND REPORTS ON FORM 8-K. . . . . . . . . . . . . . . . . . . . . . .44
SIGNATURES. . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . .49
4
Certain statements in this Annual Report on Form 10-K are forward-looking and
are identified by the use of forward-looking words or phrases such as "will be
positioned", "expects", is or are "expected", "anticipates", and "anticipated".
These forward-looking statements are based on the Company's current
expectations. Because forward-looking statements involve risks and
uncertainties, the Company's actual results could differ materially. In
addition to the factors discussed under "Business--Competition",
"Business--Product Liability Insurance" and "Business--Government Regulation",
among the factors that could cause results to differ materially from current
expectations are: (i) the general economical and competitive conditions in
markets and countries where the Company and its subsidiaries offer products and
services; (ii) changes in capital availability or costs; (iii) fluctuations in
demand for certain of the Company's products, including changes in government
procurement policy; (iv) technological challenges associated with the
development and manufacture of current and anticipated products; (v) commercial
acceptance of auto-injectors and competitive pressure from traditional and new
drug delivery methods; and (vi) delays, costs and uncertainties associated with
government approvals required to market new drugs and medical devices.
PART I
ITEM 1. BUSINESS
GENERAL
Survival Technology, Inc. (hereinafter referred to as the "Company" or "STI")
is a technology-based health care company that designs, develops and produces a
broad range of automatic injectors ("auto-injectors"), prefilled syringes and
other innovative health care devices, with a major focus on safe and convenient
participation by the patient in injection therapy. The Company also supplies
customized drug delivery system design, pharmaceutical research and development
and GMP-approved sterile product manufacturing to pharmaceutical and
biotechnology companies. The Company's products and services are designed to
improve the medical and economic value of drug therapy.
On September 11, 1996, the Company and Brunswick Biomedical Corporation
("Brunswick"), a privately-held medical device company and holder of 61% of the
Company's outstanding common stock, entered into an agreement and plan of merger
providing for the merger of Brunswick with and into the Company. It is
anticipated that the merger will be consummated during the fall of 1996. For
additional information regarding the terms of the merger, see the Company's
definitive Proxy Statement for the Annual Meeting of Shareholders for the fiscal
year ended July 31, 1996.
The Company pioneered the development of auto-injectors for the
self-administration of injectable drugs. An auto-injector is a spring-loaded,
prefilled, pen-like device that allows a patient to automatically inject a
precise drug dosage quickly, safely, reliably and without seeing the needle.
One early application of auto-injectors has been the immediate self-injection of
nerve gas antidotes by military personnel under battlefield conditions. STI is
and intends to remain a key supplier of nerve gas antidotes to the U.S. and
allied military forces. Auto-injectors also can be used effectively for
emergency administration of drugs or to facilitate the easy administration of
injectable drugs in any setting. The Company believes that auto-injectors help
to reduce the fear of injection, simplify the injection procedure, ensure
complete dose delivery, increase patient compliance and allow for cost-effective
home health care treatment.
5
The Company currently has three commercial applications for its auto-injectors.
One is an auto-injector for the self-injection of epinephrine to treat severe
allergic reactions due to bee stings, insect bites, foods and other allergies.
The second is an auto-injector for the self-injection of lidocaine to treat
cardiac arrhythmias. The third application is a morphine-filled auto-injector
for use in home health care pain management. The Company currently is
developing several new auto-injectors (See "Research and Development") including
some that will accommodate additional categories of drugs, while others will
make auto-injectors more convenient and less expensive. The Company, together
with pharmaceutical and biotechnology companies, currently is exploring
additional applications for auto-injectors.
The Company also offers ready-to-use prefilled syringes and vials, including its
proprietary CartrixTM syringe system. STI invented and manufactures the
CytoGuard-Registered Trademark-Aerosol Protection Device, a vial attachment used
to protect medical professionals from inadvertent exposure to potentially
dangerous drugs during reconstitution, particularly chemotherapeutics.
The following table sets forth the proportion of the Company's total revenues
contributed by each of its classes of products and services for the last five
fiscal years.
YEAR ENDED JULY 31
-----------------------------------------
PRODUCT/SERVICE CLASS: 1996 1995 1994 1993 1992
--------------------- ---- ---- ---- ---- ----
Automatic Injectors:
Commercial Products 36% 39% 33% 19% 16%
Military Products 51 41 29 43 15
Contract Filling and Packaging 3 5 6 16 57
CytoGuard 3 6 12 12 9
R&D Services 7 9 12 6 1
Divested Operations (1) 8 4 2
---- ---- ---- ---- ----
100% 100% 100% 100% 100%
---- ---- ---- ---- ----
Total revenue in millions(2) $31.4 $25.5 $24.9 $30.1 $40.9
----- ----- ----- ----- -----
----- ----- ----- ----- -----
(1) The Company's Medical Device Division was sold July 31, 1994 (See Note 5 in
Notes to Consolidated Financial Statements).
(2) The Company has no significant foreign operations and operates in one
industry segment. Reference is made to the three-year Consolidated
Statements of Income and Note 13 in Notes to Consolidated Financial
Statements included herein pursuant to Part II of this Form 10-K for
information concerning the Company's export sales and major customers.
The Company was incorporated in 1969 under the laws of Delaware.
PRODUCTS AND SERVICES
The Company's principal activities include: the development and production of
automatic injector products including applications of injector technology for
commercial use (emergency and non-emergency situations) where intramuscular or
subcutaneous injection is the preferred method of drug delivery and for military
use in the defense against chemical warfare; and complete sterile parenteral
contract filling and packaging services for a broad range of sterile injectable
dosage forms: vials, dental cartridges and pre-filled, ready-to-use syringes.
The Company also supplies delivery system design and pharmaceutical research and
development to major pharmaceutical and biotechnology companies.
6
The Company purchases, in the ordinary course of business, necessary raw
materials and supplies essential to the Company's operations from numerous
suppliers in the U.S. and overseas. During fiscal 1996, the Company experienced
some temporary component supply issues which have since been resolved. The
Company does not anticipate availability problems or significant supply
shortages in the future. The Company procures inventory principally when
supported by customer purchase orders and does not provide extended payment
terms to any customer.
AUTOMATIC INJECTORS
STI pioneered the use of auto-injectors beginning in the late 1950's when a
predecessor of the Company invented the auto-injector for military use. The
Company's auto-injectors are disposable, prefilled automatic syringes with which
a medically untrained person can quickly inject himself or another person with a
drug. To date, auto-injectors have been used in life-threatening situations.
However, the Company believes that their use can be extended from such
situations to the self-administered treatment of both acute and chronic
conditions in any setting.
COMMERCIAL PRODUCTS. Currently, the Company's principal commercial
auto-injectors are the EpiPen-Registered Trademark- and EpiE-ZPenTM
auto-injectors. The EpiPen and EpiE-ZPen are prescribed to patients at risk of
anaphylaxis resulting from severe allergic reactions to bee stings, insect
bites, foods, drugs and other substances as well as exercise-induced
anaphylaxis. These auto-injectors permit the immediate self-injection of
epinephrine, the drug of choice for emergency treatment of such conditions.
Each of these auto-injectors has a junior variation with a pediatric/
adolescent dosage of epinephrine.
During fiscal 1996, the Company launched the EpiE-ZPen, which is the first in a
series of new commercial auto-injector products now in development at STI. The
EpiE-ZPen has a more streamlined design to better serve the consumer market with
additional safety features and product quality enhancements. This new product
features a locking twist-top safety cap and push button activation. The Company
introduced this new product during the third quarter of its fiscal 1996 while
continuing to sell the EpiPen. The EpiE-ZPen will be positioned to expand its
use in the U.S. and international markets for food allergy indications.
The Company's epinephrine product line has historically been a seasonal product
(spring/summer) used predominately for the treatment of severe allergic
reactions from bee stings and insect bites. The Company markets the EpiPen and
EpiE-ZPen through Center Laboratories, Inc. ("Center"), a subsidiary of E.
Merck. The Company's exclusive marketing contract with Center, which extends
until the year 2000 so long as certain minimum quantity requirements are met, is
currently being amended to extend to the year 2010. Center has a co-marketing
agreement with ALK, Inc., a Danish Company, for international markets
representing 13 countries abroad. During fiscal 1996, ALK launched the EpiPen
within the United Kingdom. Epinephrine product line sales accounted for $11.2
million (36%), $9.8 million (38%) and $8.3 million (33%) of the Company's total
revenues in fiscal 1996, 1995 and 1994, respectively.
The Company is the leading manufacturer of automatic injectors used for
emergency self-administration of epinephrine. These products compete with other
available products for self-administration of epinephrine which are
non-automatic. Since their introduction in 1980, the Company has manufactured
and delivered 5.1 million EpiPens and EpiPen, Jr's. The senior version of the
epinephrine product line has a 27-month expiration date while the junior version
has a 20-month expiration date and should be replaced after that time.
7
The Company also produces the LidoPen-Registered Trademark- auto-injector which
is the same delivery system as the EpiPen, except that it is prefilled with
lidocaine hydrochloride for self- injection by persons experiencing a serious
cardiac event. The LidoPen is sold primarily in connection with the sale of the
CardioBeeper-Registered Trademark- ECG transmitter previously sold by the
Company. These sales have not been a significant source of revenue. STI will
continue to supply the LidoPen auto-injector to Brunswick Biomedical Corporation
under the terms of the Asset Purchase Agreement dated July 31, 1994. See Note 5
in Notes to Consolidated Financial Statements.
STI has a licensing agreement and long-term supply arrangement with Mylan
Laboratories ("Mylan") for the development and production of an injectable,
non-narcotic prescription drug for the management of pain. Under the terms of
this agreement, STI will develop, license and produce this new product, which
will be marketed by Mylan to family physicians, neurologists, pain specialists,
hospitals, and health maintenance organizations. The introduction is expected
in fiscal 1998 pending FDA approval.
On August 30, 1996, the Company entered into a Development and License Agreement
with a European based, global pharmaceutical company for the continuing
development and long-term supply of their prescription drug in an STI
auto-injector. This new contract is an extension of an initial development
agreement which was completed in fiscal 1996. The product is currently in phase
III clinical trials and will be introduced upon successful completion of
clinical trials and subsequent FDA approval.
The Company is currently working with other pharmaceutical companies under
development contracts to identify other drugs presently in sterile injectable
dosage forms suitable for administration using STI's proprietary auto-injector
delivery systems.
MILITARY PRODUCTS. The Company's military contracts are for two types of
auto-injectors developed by the Company. One type, the AtroPen, is capable of
holding up to 0.8cc of a drug. The other type, the ComboPen, is capable of
holding up to 3.0cc of a drug. The Company has developed and supplied the
AtroPen and ComboPen to the U.S. Army combined (by a clip-like device) in one
package known as the Mark I Antidote Kit ("Mark I"). The Company's military
auto-injectors are intended to be used by military personnel under combat
conditions for the self-administration of antidotes against the effects of
chemical warfare. The United States and several allied foreign governments
maintain stockpiles based upon the shelf-life of the antidotes (generally five
years).
To date, all DoD procurements of AtroPens, ComboPens, and Mark I's have been
restricted to sources qualified as Planned Industrial Producers for these items.
The Company is currently the only DoD Planned Industrial Producer for the
AtroPen, ComboPen and Mark I.
Sales of military auto-injector products were $16 million in fiscal 1996, of
which $14.3 million related to the industrial base maintenance contract
(discussed below) with the U.S. Department of Defense ("DoD") with the balance
derived from sales of auto-injectors to various allied foreign governments.
This represents a 52% increase over the $10.5 million generated from sales of
military auto-injectors in fiscal 1995, of which $7.4 million was derived from
DoD contracts.
During the first quarter of fiscal 1997, STI's industrial base maintenance
contract with the DoD was extended through November 30, 1996. The Company
expects the first of two one-year renewal options to be exercised by the DoD
before November 30, 1996. The industrial base maintenance contract calls for
the retention of key personnel and facilities to assure expertise
8
for manufacturing auto-injectors containing nerve gas antidotes, the storage of
serviceable material from expired auto-injectors, the management of the U.S.
Army's shelf-life extension program and new product orders. A surge capability
provision allows for the coverage of defense mobilization requirements in the
event of rapid military deployment. In addition, the contract has been expanded
during fiscal 1996 to include the pre-stocking of critical components at STI's
St. Louis manufacturing facility to enhance readiness and mobilization
capability. This contract is part of program by the DoD to assure adequate
supplies of critical items in the event of war.
Revenue from the base maintenance contract was $14.3 million, $7.4 million and
$5.7 million in fiscal 1996, 1995 and 1994, respectively. Fiscal 1997 revenue
from this contract, including production of automatic injectors, is expected to
be consistent with fiscal 1996 levels. During the current year, the Company
became a qualified manufacturer of the Diazepam auto-injector for the DoD. The
Diazepam auto-injector is a ComboPen filled with the drug diazepam (valium).
Diazepam product deliveries, supplied as part of the base maintenance contract,
generated revenue of $2.7 million in its initial year. Sales to the DoD for
this product are expected to continue in fiscal 1997.
The U.S. Government continues to investigate new automatic injection delivery
systems, as well as new drugs and antidotes, to be placed in new or existing
automatic injectors. In fiscal 1996, the Company completed the initial phase of
its contract with the U.S. Army to develop a single, multi-chamber automatic
injector. STI submitted several proposals in response to the Army's request to
evaluate and consider producing an alternative version of this product. During
the current year, one of these design alternatives was accepted by the Army who
then submitted this proposal to the Food and Drug Administration ("FDA") for
their review. This review is expected to be complete during the second quarter
of fiscal 1997. If developed, the earliest practical date for fielding this new
injector would be fiscal 1999. Procurement and deployment of such a
multi-chamber auto-injector would likely replace the Mark I and reduce the
current domestic market for AtroPen and ComboPen auto-injectors over time.
Sales of STI's auto-injectors to allied foreign governments decreased $1.4
million (45%) from $3 million in fiscal 1995. Although these revenues declined,
the Company's intensified efforts to expand sales of military products
internationally has resulted in orders from several new customers during fiscal
1996 and 1997. To this end, the Company secured an AtroPen order from the
Republic of Germany for $2.7 million during the first quarter of fiscal 1997.
Product deliveries are anticipated to commence in the second quarter of fiscal
1997 with the order being completed by the end of fiscal 1997. At present, the
German government has indicated that their annual need for this product over the
next two to four years will be comparable to their original order, although at
this time no additional orders have been placed. In an effort to secure
additional business in the highly competitive international marketplace, the
Company is implementing a cost reduction program covering its military product
line to be more cost competitive and improve margins.
The Company has also introduced auto-injector systems that can store compounds
in dry form and mix them in solution prior to administration. Limited
quantities of this product (BinaJect) have been manufactured and sold to a
foreign allied government. Many of the new nerve agent antidotes require this
technology because of their limited shelf-life or instability in solution. In
addition, market expansion efforts in regions subject to high temperatures will
also require this specialized auto-injector drug delivery system. All export
sales of military auto-injectors require U.S. State Department approval.
9
CONTRACT FILLING AND PACKAGING
STI has complete sterile parenteral contract filling and packaging services for
a broad range of sterile injectable dosage forms which includes vials, dental
cartridges and pre-filled, ready-to-use syringes. The Company's proprietary
CartrixTM syringe system is a line of unit-dose, disposable, prefilled syringes
suitable for a broad range of injectable drugs. The Company fills Cartrix
syringes and other lines of vials, dental cartridges and syringes with
pharmaceuticals supplied by the contracting party and formulated by the Company
to the contracting party's specifications. Revenues from these activities
aggregated $918,800, $1,237,500 and $1,646,000 in fiscal years 1996, 1995 and
1994, respectively.
STI designs and manufactures delivery systems tailored to the requirements of
its customers' products. Presently, these arrangements, in the aggregate, do
not produce significant revenues. The Company is actively negotiating with
certain pharmaceutical companies to develop and manufacture generic forms of
selected liquid injectable drugs that are nearing their patent expiration.
These products would be in various dosage forms including single and multi-dose
vials and prefilled syringes. Additionally, STI is working with other
pharmaceutical and biotechnology companies for continued expansion of this
business which includes syringes with sterile water used to reconstitute drugs
in a dry compound state.
CYTOGUARD
The Company invented and now manufactures the patented CytoGuard-Registered
Trademark- Aerosol Protective Device. The CytoGuard is a vial attachment used
to reduce the risk of exposure of health care professionals while reconstituting
toxic drugs, particularly chemotherapeutics, being administered to patients.
The Company has an exclusive License and Supply Agreement with a subsidiary of
Bristol Myers-Squibb ("BMS") for the distribution of CytoGuard in the United
States. While this agreement expires in December 1996, the Company is exploring
other business strategies for CytoGuard. Production and delivery of CytoGuards
generated revenues of $865,700 (3%), $1,592,700 (6%) and $3,042,000 (12%) of
consolidated sales in fiscal years 1996, 1995 and 1994, respectively. The
Company does not expect further CytoGuard sales to BMS in fiscal 1997.
R&D SERVICES
STI provides fully validated formulation and aseptic filling services and
regulatory assistance for those pharmaceutical and biotechnology companies not
currently possessing such capabilities. The Company also supplies customized
drug delivery system design, GMP-approved sterile product manufacturing and
pharmaceutical research and development to a number of different companies.
Development programs include feasibility and stability studies as well as the
manufacturing of clinical trial materials in the Company's St. Louis pilot
plant. If feasibility and stability studies are successful and all regulatory
approvals are received, the Company anticipates contracts in the coming years to
manufacture these products in vials, prefilled syringes or STI's proprietary
auto-injector systems. Revenue from customer-funded research and development
activities were $2.3 million, $2.3 million and $2.9 million in fiscal years
1996, 1995 and 1994, respectively. The Company expects fiscal 1997 revenues
from funded R&D activities to be comparable with historical levels.
10
COMPETITION
The Company operates in a highly competitive sector of the health care industry.
STI competes directly with companies that manufacture drug injection devices and
indirectly with companies that develop and market drug delivery systems which
are alternatives to injection. Competition from large pharmaceutical companies,
joint ventures, and others is intense and expected to increase. Many of these
companies have substantially greater capital resources, larger research and
development staffs and facilities than the Company, and substantially greater
experience in the manufacturing and marketing of pharmaceutical products as well
as obtaining regulatory approvals. The activities of these entities represent
significant long-term competition for the Company.
STI's auto-injectors compete with a number of other drug delivery systems,
including those for the self-injection of epinephrine for treating anaphylaxis,
which are not automatic. The Company's military auto-injectors compete in price
and quality with auto-injectors sold by companies in Holland, South Korea and
Israel. Major competitors in this area are Solvay Duphar B.V. (ComboPens only)
and Astra Tech, both large international pharmaceutical manufacturers as well as
Shalon Ltd, an Israeli-based manufacturer of chemical protective equipment,
including auto-injectors (AtroPens only).
The Company's contract filling and packaging services are in an intensely
competitive field which is presently dominated by larger pharmaceutical
companies, many having greater resources than the Company, and other disposable,
prefilled syringe systems presently available which can be less expensive. A
very small group of independent companies and a few pharmaceutical companies
offer contract syringe filling services similar to those that the Company
offers.
BACKLOG AND RENEGOTIATION
As of July 31, 1996, the Company had a backlog of orders approximating $8
million, of which $4.9 million related to production and delivery of commercial
products and services and $3.1 million related to military products. The
majority of this backlog is scheduled to be completed during the first quarter
of fiscal 1996. This compares with commercial product sales backlog of $2.5
million and military auto-injector sales backlog of $1.3 million at July 31,
1995. See "Management's Discussion and Analysis of Financial Condition and
Results of Operations" included herein pursuant to Part II of this Form 10-K.
There is no material portion of the Company's business which is subject to
renegotiation of profits. The Company's supply contracts with the DoD are
subject to post-award audit and potential price redetermination. From time to
time, the DoD makes claims for pricing adjustments with respect to completed
contracts. At present, no claims are pending.
All U.S. Government contracts provide that they may be terminated for the
convenience of the Government as well as for default. Upon termination for
convenience of cost reimbursement type contracts, the Company would be entitled
to reimbursement of allowable costs plus a portion of the fixed or target fee
related to work accomplished. Upon convenience termination of fixed-price
contracts, the Company normally would be entitled to receive the contract price
for items which have been delivered under the contract, as well as reimbursement
for allowable costs for undelivered items, plus an allowance for profit thereon
or adjustment for loss if completion of performance would have resulted in a
loss. No such contract terminations are anticipated by the Company.
11
PATENTS, TRADEMARKS, AND LICENSES
The Company considers its proprietary technology to be important in the
development, marketing and manufacture of its products and seeks to protect its
technology through a combination of patents and confidentiality agreements with
its employees and others. Patents covering important features of the Company's
current principal auto-injector products have expired. This loss of patent
protection could have an adverse affect on the Company's revenues and results of
operations. STI is currently developing a new generation of auto-injector
products (See "Research and Development" following) for which a number of
patents have been granted to the Company. Over the last few years, the Company
was granted U.S. patent protection for several of its new auto-injector drug
delivery systems, designed for fast and reliable patient self-administration of
the expanding range of new pharmaceutical and biotechnology products that
require injection. Some of these patents cover the EpiE-ZPen, whose product
launch was in fiscal 1996. See "Commercial Products" above.
The Company intends to file for additional patent protection for all of its new
products currently under development. These products are expected to replace or
supplement the Company's existing line of auto-injectors over time. The Company
has several important patents related to thrombolytic therapy. These patents
broaden the Company's patent protection, especially in the area of intramuscular
administration of protein thrombolytic agents, including t-PA.
The Company owns a number of trademarks in the U.S. and other countries. The
Company is also licensed in the U.S. and other countries under patents and
trademarks owned by others. In the aggregate, these trademarks and licenses are
of material importance to the Company's business, with the most significant
being the license and supply agreements with a division of American Home
Products Corporation ("licensor") which grants the Company an exclusive license
to manufacture, use and sell the licenser's patented product within the
Company's auto-injectors (ComboPens). The term of the supply agreement extends
through fiscal 1997 and automatically continues for consecutive one-year renewal
periods.
RESEARCH AND DEVELOPMENT
The Company expended $606,600, $943,000, and $1,024,600 on research and
development activities in fiscal 1996, 1995 and 1994, respectively. The Company
intends to continue to expend funds on the activities discussed below and
expects that amounts spent on research and development in fiscal 1997 to be
higher than previous fiscal years.
STI is currently developing a new family of auto-injectors to accommodate the
expanding variety of injectable drugs that demand safe and convenient patient
self-administration. These new auto-injectors are designed for use in emergency
situations and for any episodic treatment where an intramuscular or subcutaneous
injection is the preferred drug delivery method. The Company is currently
exploring certain applications of these new auto-injectors which will be subject
to certain regulations prior to the product reaching the marketplace. See
"Government Regulation" following.
12
The Company has patented auto-injector systems that can store compounds in dry
form and reconstitute them in solution prior to administration. An increasing
array of biotechnology products and many traditional therapies require this
technology because of their limited shelf-life or instability in solution. STI
also has a single-chambered auto-injector for intramuscular and subcutaneous
injection which utilize a very thin (27 gauge) needle for potential new
applications.
PRODUCT LIABILITY INSURANCE
The Company maintains product liability coverage for its medical products and
its commercial pharmaceutical products, including the LidoPen, EpiPen,
EpiE-ZPen, and the Cartrix syringe system. The Company will continue to
maintain liability insurance as it relates to divested operations to cover any
potential claims incurred but not reported prior to their disposition.
Although, the Company's management is of the opinion that, with respect to
amounts, types, and risks insured, the insurance coverage is adequate for the
business conducted by the Company, there can be no assurance that such insurance
will provide sufficient insurance coverage against any or all potential product
liability claims.
GOVERNMENT REGULATION
The business of the Company is highly regulated by governmental entities,
including the FDA and corresponding agencies of states and foreign countries.
The summary below does not purport to be complete and is qualified in its
entirety by reference to the complete text of the statutes and regulations cited
herein.
As a manufacturer of auto-injectors and prefilled syringes, the Company's
products are subject to regulation by the FDA under the Federal Food, Drug and
Cosmetic Act ("Act"). All of the Company's auto-injectors are "new drugs" and
may be marketed only with the FDA's approval of a NDA or a supplement to an
existing NDA. The Company currently holds approved NDAs for each of its
existing auto-injector products. The use of the Company's existing
auto-injectors to administer FDA approved drugs generally would require the
filing of a NDA or supplement to an existing NDA. In addition, the introduction
of the Company's new generation auto-injectors, such as the EpiE-ZPen which
received approval in August 1995, will require FDA approvals based on data
demonstrating the safety and effectiveness of the drug delivered by these
auto-injectors. There is no assurance that the NDAs will be processed in a
timely manner or that FDA ultimately will approve such NDAs.
The Company's Cartrix-TM- and other prefilled syringe systems are also regulated
as drugs; however, the requisite FDA approval is held by the supplier of the
drug that the Company fills into the syringe. To the extent the Company's
auto-injectors or Cartrix-TM- syringe system are expected to be used to
administer new drugs under development, FDA approval to market such drugs first
must be received by the pharmaceutical manufacturer. Obtaining the requisite
FDA approval is a time consuming and costly process through which the
manufacturer must demonstrate the safety and effectiveness of a new drug
product.
The Cytoguard Aerosol Protection Device is regulated and currently marketed as a
medical device. Certain of the Company's new auto-injectors also may be
regulated as medical devices. Such devices are subject to a pre-market
notification process. The requisite FDA filing must contain information that
establishes that the new product is substantially equivalent to an existing
device available for the same intended use. The FDA must either approve or deny
the application or require further information within 90 days of its submission.
Products which do
13
not receive approval through the FDA's pre-market notification process are
subject to the FDA's much lengthier and more complex pre-marketing approval
procedures.
In connection with its manufacturing operations, the Company must comply with a
variety of regulations, including the FDA's Good Manufacturing Practice ("GMP")
regulations, and its manufacturing facilities are subject to periodic
inspections. The Company's St. Louis facility underwent an inspection by the
FDA during fiscal 1996 in which there were no material issues brought to
management's attention.
Suppliers of bulk drugs for filling into the Company's syringe systems, as well
as some subcontractors who manufacture components for the Company's medical
devices, also are subject to FDA regulation and inspection. The Company has
only limited control over these other companies' compliance with FDA
regulations. Failure of these companies to comply with FDA requirements could
adversely affect the Company's ability to procure component parts, market
finished products and may cause the Company's products made with non-compliant
components to be adulterated or misbranded in violation of the Act, subjecting
the products to a variety of FDA administrative and judicial actions.
The FDA is empowered with broad enforcement powers. The FDA may initiate
proceedings to withdraw its approval for marketing of the Company's products
should it find that the drugs are not manufactured in compliance with GMP
regulations, that they are no longer proven to be safe and effective, or that
they are not truthfully labelled. Noncompliance with GMP regulations also can
justify nonpayment of an existing government procurement contract and, until the
deficiencies are corrected to FDA's satisfaction, can result in a nonsuitability
determination, precluding the award of future procurement contracts.
For any of the Company's auto-injectors and syringe systems, noncompliance with
FDA regulations could result in civil seizure of the drugs, an injunction
against the continued distribution of the drugs or criminal sanctions against
the Company. The Company's medical devices also are subject to seizure by the
FDA through administrative or judicial proceedings. In addition, the FDA may
impose civil money penalties for most violations of law and may order that
defective devices be recalled, repaired or replaced or that purchasers be
refunded the cost of the device.
The Company also is subject to regulation by other federal and state agencies
under various statutes, regulations and ordinances, including environmental
laws, occupational health and safety laws, labor laws and laws regulating the
manufacture and sale of narcotics.
EMPLOYEES
As of September 30, 1996, the Company employed a total of 251 employees; 218
employees work at the Company's plant and warehouse facilities in St. Louis,
Missouri; 10 employees work at the Company's facility in the United Kingdom and
23 employees work at the Company corporate headquarters in Rockville, Maryland
(see "Properties"). Effective March 1, 1994, the Company entered into a
five-year agreement with the Teamsters Local Union No. 688 ("Teamsters") which
is affiliated with the International Brotherhood of Teamsters, Chauffeurs,
Warehousemen and Helpers of America. Teamsters are the exclusive agent for all
production and maintenance employees of the Company at its St. Louis facility.
Approximately 118 employees are covered by this collective bargaining agreement.
The new labor union contract did not significantly change the mix of benefits
previously provided to such employees.
14
ITEM 2. PROPERTIES
The Company's corporate headquarters occupy approximately 17,000 square feet in
an executive office building complex located in Rockville, Maryland. STI signed
a ten-year lease agreement for this office space beginning January 1992. This
facility contains corporate administration; human resources; finance; commercial
business development; and product, design and development functions. During the
fourth quarter of fiscal 1995, the Company initiated a restructuring plan which
includes the relocation of its corporate office to reduce occupancy costs while
subleasing this current office space. In October 1996, the Company signed a
letter of intent to sublease its corporate office space in Rockville, Maryland
and entered into a new lease in Columbia, Maryland. See Note 3 in Notes to
Consolidated Financial Statements.
The Company's primary pharmaceutical operations are located in St. Louis,
Missouri. These facilities are used primarily for formulation, aseptic filling,
assembly and final packaging of the Company's auto-injectors, vials and
prefilled syringes. The St. Louis manufacturing facilities consist of eight
separate buildings occupying over 90,000 square feet. The principal St. Louis
facilities are leased pursuant to lease agreements which begin to expire in
fiscal 1996 and 1997 but contain renewal options for additional five-year and
ten-year periods. See "Leases" in Note 11 of the Notes to Consolidated Financial
Statements included herein pursuant to Part II of this
Form 10-K. The Company believes that its current production facilities in St.
Louis, Missouri are suitable and adequate for the Company's current business.
STI International Limited is located in the Medway City Industrial Estate, an
enterprise zone in Rochester, Kent in the United Kingdom. The facility consists
of one modern building occupying approximately 4,200 square feet which is used
primarily for aseptic assembly and final packaging of the Mediject morphine
automatic injector under a contract with the United Kingdom Ministry of Defense.
This facility is also used as a sales and marketing office to promote STI's
commercial and military products in Europe and the Middle East. The facility is
leased pursuant to a lease which expires in 2010.
ITEM 3. LEGAL PROCEEDINGS
Information required by this Item 3 is included in Note 11 "Commitments and
Contingencies - Litigation," of the Notes to Consolidated Financial Statements
included herein pursuant to Part II of this Form 10-K.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
There were no matters submitted by the Company during the fourth quarter of
fiscal 1996 to a vote of security holders, through the solicitation of proxies,
or otherwise.
15
EXECUTIVE OFFICERS OF THE REGISTRANT
The following table lists, as of September 30, 1996, the names and ages of all
executive officers of the Company, and their positions and offices held with the
Company.
NAME AGE PRESENT POSITIONS WITH THE COMPANY
- ---- --- ----------------------------------
James H. Miller 58 Chairman, President and
Chief Executive Officer
Jeffrey W. Church 39 Sr. Vice President-Finance and
Chief Financial Officer
Glenn F. Wickes, Jr. 51 Sr. Vice President-Pharmaceutical Operations
Mark D. Ruby 43 Vice President - Marketing and Sales
There are no family relationships among the executive officers and directors of
the Company as a group.
Mr. Miller joined the Company as President in June 1989, was elected Chief
Executive Officer in June 1990 and was elected Chairman of the Board in April
1996. In November 1993, Mr. Miller assumed the additional post of chairman and
chief executive officer of Brunswick Biomedical Corporation while continuing his
position with STI. Prior to joining the Company, Mr. Miller served as Executive
Vice President of Beecham Laboratories from February 1987 to May 1989,
responsible for the Pharmaceutical and Animal Health Divisions. Prior to
joining Beecham, Mr. Miller spent ten years with Frank J. Corbett, Inc.
(Advertising Agency) as Executive Vice President and fourteen years in marketing
management with Abbott Laboratories.
Mr. Church joined the Company in April 1986 as Corporate Controller, became Vice
President - Finance and Chief Financial Officer in June 1988 and became Senior
Vice President - Finance and Chief Financial Officer in November 1994. Prior to
joining the Company, Mr. Church was with the accounting firm of Price Waterhouse
LLP seven years.
Mr. Wickes joined the Company as Vice President of Pharmaceutical Operations in
August 1993 and became Senior Vice President of Pharmaceutical Operations in
November 1994. Prior to joining the Company, Mr. Wickes served as Executive
Vice President of Duoject Medical Systems from December 1991 to July 1993,
responsible for new business development and technical affairs for this
specialized drug delivery company. Prior to joining Duoject, Mr. Wickes was
Director of Operations, Marketing and New Business Development for Adria Sterile
Products, Inc. from April 1988 until December 1991. Prior to joining Adria, Mr.
Wickes held senior executive positions at Summa Manufacturing Corporation and
Ben Venue Laboratories, Inc. Mr. Wickes'employment with the Company was
terminated in October 1996.
Mr. Ruby joined the Company as Vice President of Marketing and Sales in January
1996. Prior to joining the Company, Mr. Ruby served in the same capacity at
Jobst Institute, Inc. from March 1992 to December 1995 where he was responsible
for domestic and international marketing, sales and service. Prior to joining
Jobst, Mr. Ruby served in various capacities including Director of Business
Development and Director of Domestic Sales for Medisense, Inc. from July 1988 to
February 1991. Prior to joining Medisense, Mr. Ruby held various positions with
Baxter Healthcare, Inc. from July 1979 to June 1988.
16
PART II
ITEM 5. MARKET FOR THE REGISTRANT'S COMMON STOCK AND RELATED STOCKHOLDER
MATTERS
The Company's common stock is traded in the over-the-counter market and is
quoted in the NASDAQ National Market System under the symbol STIQ. The
following table sets the high and low sales prices of the Company's common stock
for each fiscal quarter during the two year period ended July 31, 1996, as
reported on the NASDAQ National Market System.
1996 1995
---------------- ----------------
QUARTER HIGH LOW HIGH LOW
--------------------------------------------------------
First $9 1/2 $6 1/2 $8 3/4 $6 1/2
Second 10 1/4 7 1/4 9 1/4 6 3/4
Third 10 1/8 7 1/2 10 7 1/4
Fourth 11 7/8 8 1/4 9 1/2 7 1/4
--------------------------------------------------------
The Board of Directors has not declared any dividends on the Company's stock
since its organization. As of September 30, 1996, the number of shareholders of
record was 390.
17
SELECTED FINANCIAL DATA
Survival Technology, Inc. - Five-Year Summary of Operations and Financial
Information
(In Thousands, Except Per Share Data)
Year Ended July 31 1996 1995 1994 1993 1992
Operations:
Net sales $31,385 $25,487 $24,856 $30,075 $40,931
Gross profit 8,957 8,259 8,657 9,726 8,133
Operating income (1) 2,274 890 1,928 3,111 2,153
Gain on sale of Medical Device
Division 1,562
Other income (expense),
net (300) (180) 81 (106) 158
Income before income
taxes and extraordinary item 1,974 710 3,571 3,005 2,311
Provision for income tax 698 250 1,442 1,160 634
------- ------- ----- ------- -------
Income before
extraordinary item 1,276 460 2,129 1,845 1,677
Extraordinary item 37
------- ------- ----- ------- -------
Net income $ 1,276 $ 460 $ 2,129 $ 1,845 $ 1,714
------- ------- ----- ------- -------
------- ------- ----- ------- -------
Per share data:
Income before
extraordinary item $ .41 $ .15 $ .68 $ .60 $ .55
Extraordinary item .01
------- ------- ----- ------- -------
Net income $ .41 $ .15 $ .68 $ .60 $ .56
------- ------- ----- ------- -------
------- ------- ----- ------- -------
Average common shares and
common share equivalents
outstanding 3,117 3,102 3,118 3,092 3,086
------- ------- ----- ------- -------
------- ------- ----- ------- -------
Financial position:
Current assets $14,414 $11,553 $10,227 $10,022 $13,937
Working capital 4,204 3,668 5,193 5,635 5,782
Fixed assets, net 14,815 14,209 11,893 9,801 7,818
Total assets 31,085 27,715 24,201 21,911 22,487
Long-term debt 1,184 1,486 1,620 2,740 2,014
Shareholders' equity 17,469 16,150 15,690 13,558 11,149
(1) Fiscal 1996 and 1995 operating income includes a restructuring charge of
$321,900 and $450,000, respectively.
The Company has not declared any dividends on its common stock since its
inception.
18
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
INTRODUCTION
The following discussion and analysis of financial condition and results of
operations cover the fiscal years ended July 31, 1996, 1995 and 1994.
RESULTS OF OPERATIONS
1996 AND 1995
The Company reported net income of $391,400 ($.12 per share) and $1,276,000
($.41 per share) on sales of $8.6 million and $31.4 million for the fourth
quarter and fiscal year ended July 31, 1996. This compares with net income of
$257,400 ($.08 per share) and $460,500 ($.15 per share) on sales of $8.5 million
and $25.5 million for the quarter and year ended July 31, 1995. Net income
improved $134,000 ($.04 per share or 52%) in the current quarter and nearly
tripled increasing $815,500 ($.26 per share) in the current year when compared
with the same prior year periods. While remaining relatively constant in the
fourth quarter, revenue increased $5.9 million (23%) during the current year
when compared with the corresponding prior year on the strength of higher U.S.
military product and EpiPen-Registered Trademark- auto-injector sales.
Military sales increased $1.2 million (37%) to $4.4 million in the current
quarter and $5.5 million (52%) to $16 million in fiscal 1996 when compared with
the concurrent prior year periods. These increases were due to shipments of
military auto-injectors during the current quarter coupled with additional
services provided as part of the Industrial Base Maintenance Contract with the
U.S. Department of Defense ("DoD"). Revenues under this DoD contract increased
$1.3 million (61%) to $3.4 million for the quarter and increased $6.9 million
(92%) to $14.3 million for the year ended July 31, 1996 when compared with the
same periods last year. Product deliveries included sales of the Diazepam
auto-injector which was approved by the U.S. Food and Drug Administration
("FDA") in December 1995. Revenues for this new injector were $1.8 million and
$2.7 million for the quarter and year ended July 31, 1996. Additional services
provided to the DoD during the current year included the prestocking of critical
components at STI's St. Louis manufacturing facility to enhance readiness and
mobilization capability. These increases were partially offset by declines in
revenue from international military products of $132,900 (13%) and $1.4 million
(45%) for the quarter and year ended July 31, 1996 compared with the same
periods last year.
The Industrial Base Maintenance Contract is a continuation of the program
adopted in 1993 by the DoD to assure adequate supplies of critical items in the
event of war. STI is the only U.S. supplier of nerve gas antidote
auto-injectors, which were widely deployed by U.S. allied forces during the
Persian Gulf War. This contract calls for the retention of key personnel and
facilities to assure expertise for manufacturing auto-injectors containing nerve
gas antidotes, the storage of serviceable material from expired auto-injectors,
the management of the DoD's shelf-life extension program and new product orders.
This contract has a surge capability provision allowing for the coverage of
defense mobilization requirements in the event of rapid military deployment.
Moreover, the contract was expanded in fiscal 1996 to include the prestocking of
critical components at STI's St. Louis manufacturing facility to enhance
readiness and mobilization capability. Revenue from this component prestocking
program was $1.7 million in fiscal 1996. The Company believes this contract
represents a cost-saving measure for the Government by allowing the DoD to
consolidate its warehouse depots and personnel necessary to manage this
material.
19
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (CONTINUED)
Commercial products and services generated revenues of $4.3 million and $15.4
million for the quarter and year ended July 31, 1996 compared with $5.3 million
and $15 million in the respective prior year periods. While these revenues were
comparable for the years ended July 31, 1996 and 1995, a decrease of $1 million
(19%) in the fourth quarter of fiscal 1996 was primarily attributable to the
timing of CytoGuard-Registered Trademark- sales ($800,100) which occurred during
the previous quarter of the current fiscal year. The fiscal 1996 commercial
revenue increase resulted primarily from higher sales of the Company's
epinephrine auto-injector product line ($1.4 million or 14%) which was partially
offset by lower revenue ($1 million or 36%) from various other contract filling
and packaging work which includes CytoGuard.
The EpiPen and EpiE-ZPen are automatic injectors that contain epinephrine which
are indicated for immediate use by persons in the emergency treatment for severe
allergic reactions to bee stings, insect bites and ingestion of certain foods.
The EpiE-ZPen is a smaller, more streamlined auto-injector that is easier to use
than previous injectors and resembles an ordinary fountain pen with a pocket
clip for easy carrying. Revenues from these products totalled $3.4 million and
$11.2 million for the quarter and year ended July 31, 1996 compared with $3.5
million and $9.8 million in the corresponding prior year periods. While these
revenues were comparable in the quarter, the epinephrine product line
experienced continued growth of $1.4 million (14%) in fiscal 1996 when compared
with fiscal 1995. This increase can be attributed to the expanded promotional
efforts over the last several years by Center Laboratories, Inc. ("Center"),
STI's exclusive distributor of the EpiPen and the EpiE-ZPen. The Company
anticipates epinephrine product sales to continue improving over prior year
levels with Center's continuing expansion of marketing efforts in the U.S. and
international markets coupled with the recent introduction of the EpiE-ZPen.
The Company's patented CytoGuard Aerosol Protective Device is designed to reduce
the risk of exposure of health care professionals while reconstituting toxic
drugs administered to patients, such as chemotherapeutics. CytoGuard, sold
exclusively to Bristol-Myers Squibb ("BMS") for distribution in the U.S. with
BMS products, generated revenue of $865,800 in fiscal 1996 which represents a
$726,900 (46%) decline from fiscal 1995 revenue of $1.6 million. As previously
reported, lower in-market sales of these BMS products continued to adversely
effect CytoGuard sales during fiscal 1996. Although no sales of CytoGuard are
expected in fiscal 1997, the Company is exploring various business strategies
for this product.
STI has development programs that include feasibility and stability studies as
well as the manufacturing of clinical trial materials in the Company's St. Louis
pilot plant. If feasibility and stability studies are successful and all
regulatory approvals are received, the Company anticipates contracts in the
coming years to manufacture these products in vials, prefilled syringes or STI's
proprietary auto-injector systems. These customer-funded development programs
generated revenue of $2.3 million in both fiscal 1996 and 1995, respectively.
Gross margins were 31% and 29% for the quarter and year ended July 31, 1996
compared to 33% and 32% for the quarter and year ended July 31, 1995. The
decrease in gross margins were due to various factors including component supply
issues which disrupted production in fiscal 1996 coupled with higher military
product sales which have inherently lower margins. The Company has resolved
this component supply issues and is working to improve gross margins through the
completion of several manufacturing cost reduction programs currently in
progress.
20
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (CONTINUED)
Selling, general and administrative expenses decreased $122,000 (10%) in the
current quarter and $309,600 (7%) in fiscal 1996 when compared with the same
prior year periods. These anticipated decreases resulted primarily from the
absence of certain administrative costs related to organizational changes made
during fiscal 1996 to streamline reporting relationships. This was done in
conjunction with the previously reported restructuring plan adopted by the Board
of Directors in fiscal 1995. See Note 3 in Notes to Consolidated Financial
Statements.
Research and development expenditures decreased $316,700 (34%) in fiscal 1996
when compared with fiscal 1995. This was due to the timing of expenditures
related to certain projects which have been deferred into fiscal 1997. The
Company remains focused on development efforts to its new generation
auto-injector products designed for outpatient/in-home use. These products
target infrequent injection of medication in acute episodes of disease as well
as treatment of chronically ill patients. This will result in higher R&D
expenses in fiscal 1997 when compared to fiscal 1996 and will be comparable to
historical levels.
Depreciation and amortization remained relatively constant increasing $68,300
(4%) in fiscal 1996 when compared with fiscal 1995. This increase includes a
significantly lower amortization expense ($142,500 or 44%) during the current
year due to selected patent write-offs which occurred in fiscal 1995. Absent
amortization, depreciation expense increased $210,800 (14%). As previously
reported, higher depreciation expense was anticipated due to increased levels of
capital expenditures made over the last two fiscal years.
As part of the restructuring plan adopted in fiscal 1995, the Company initiated
certain organizational changes during fiscal 1996 resulting in additional
charges of $321,900 related to employee severance expense in fiscal 1996. These
charges are in addition to a $450,000 charge assessed against fiscal 1995
earnings for relocating STI's corporate headquarters to reduce occupancy costs.
To this end, the Company is planning to move its corporate office facility from
Rockville, Maryland, to Columbia, Maryland. See Note 3 in Notes to Consolidated
Financial Statements.
Other expense, net of other income, increased $119,900 (67%) in the current year
when compared with the last year. This was primarily attributable lower royalty
income for the year ended July 31, 1996 which the Company receives from the sale
of its Medical Device Division to Brunswick Biomedical Corporation in fiscal
1994. Interest expense was comparable increasing slightly by $14,300 (4%) in
fiscal 1996.
1995 AND 1994
The Company reported net income of $460,500 ($.15 per share) on sales of $25.5
million for the fiscal year ended July 31, 1995. This compares with net income
of $2.1 million ($.68 per share) on sales of $24.9 million for the fiscal year
ended July 31, 1994. Fiscal 1994 operating results include a $953,000 ($.30 per
share) non-recurring gain, net of tax, from the fourth quarter sale of the
Company's Medical Device Division ("MDD"). Fiscal 1995 operating results were
adversely effected by a $292,500 ($.09 per share) restructuring charge, net of
tax, recorded in its fourth quarter. Absent this restructuring charge in fiscal
1995 and the non-recurring gain in fiscal 1994, earnings for the fiscal year
ended July 31, 1995 would have decreased by $422,500 ($.14 per share) when
compared with fiscal 1994 operating results.
21
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (CONTINUED)
Revenues in fiscal 1995 increased $2.5 million (11%) over the prior year,
exclusive of the $1.9 million in revenues generated by the MDD which was sold in
fiscal 1994. Contributing to this sales improvement was a $3.4 million (48%)
increase in military product sales which was partially offset by a $900,000 (6%)
decrease in commercial sales. While current year revenues were increasing over
the prior year, gross margins were decreasing from 35% in fiscal 1994 to 32% in
the current fiscal year. This decline in gross margins was attributable to
several factors including the plant shutdown during the first quarter of fiscal
1995, lower revenues from funded R&D activities and lower margin foreign
military auto-injector sales. The Company's competitive bid for this foreign
military contract anticipated a lower margin in pursuit of contact award to
better position itself for future business.
Military product sales in fiscal 1995 consisted of $7.4 million in revenue from
the U.S. DoD which represents a $1.8 million (31%) increase over fiscal 1994.
Foreign military sales were $3 million in fiscal 1995 which represents a $1.6
million (113%) increase over the prior year. This increase is attributable to
the Company's competitive bid for a foreign military contract anticipating a
lower margin in pursuit of contract award. This was done in an effort to better
position STI for additional future business and minimize bid losses to a
competitor with local manufacturing operations, which occurred in fiscal 1994.
The decline in commercial sales is attributable to lower revenues from both
CytoGuard sales and funded R&D activities. These lower revenues were partially
offset by a growth in revenues from the EpiPen auto-injector which aggregated
$9.8 million in fiscal 1995 and represents a $1.4 million (17%) increase over
fiscal 1994. This increase is primarily attributable to expanded promotional
efforts over the last two years by Center. CytoGuard revenues were $1.6 million
in fiscal 1995, which represents a 48% decrease from the $3 million recognized
in fiscal 1994. During fiscal 1994, the Company under the direction of BMS,
changed the packaging of this product from a single unit to a multi-unit
package. Creation of inventories of the new multi-unit package coupled with
lower in-market sales of BMS' products resulted in lower CytoGuard sales in
STI's fiscal 1995 with this decline expected to continue in fiscal 1996.
Revenues from these development contracts during the current year were $2.3
million, which represents a $598,000 (21%) decrease from last year.
Selling, general and administrative expenses ("SG&A") decreased $298,300 (7%)
during fiscal 1995 when compared with fiscal 1994. This decrease resulted
primarily from the absence of SG&A expenses related to the MDD which was sold in
July 1994. During the fourth quarter of fiscal 1995, the restructuring plan was
approved by the Company's Board of Directors resulting in a $450,000
restructuring charge against operations. This restructuring plan is expected
to further reduce SG&A expenses in fiscal 1996 and beyond.
Research and development expenditures remained relatively constant decreasing
$81,600 (8%) in the current year.
Depreciation and amortization increased $570,100 (46%) in fiscal 1995 when
compared with the prior year. The Company continues to invest significantly in
capital expenditures (see "Balance Sheet Review") and, as previously reported,
expected depreciation expense to increase in the current period and in future
periods. Also contributing to this increase was the accelerated
amortization/write-off of certain patent costs which the Company does not
believe will provide previously anticipated future benefit.
22
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (CONTINUED)
Other income, net of other expenses, decreased $1.9 million in the current
fiscal year primarily due to the $1.6 million pre-tax gain on the sale of the
MDD in fiscal 1994. See Note 5 in Notes to Consolidated Financial Statements.
Also contributing to this increase was higher interest expense of $302,300 in
fiscal 1995 due to higher levels of bank borrowings as well as the commencement
of interest payments on the outstanding note payable to Syntex Laboratories,
Inc. (see "Liquidity and Capital Resources" following).
LIQUIDITY AND CAPITAL RESOURCES
The Company has a revolving credit agreement ("Agreement") with Merrill Lynch
Business Financial Services, Inc. ("MLBFS") with a maximum commitment of $5
million. Outstanding borrowings under the Agreement totalled $3.9 million at
July 31, 1996 with an interest rate equal to the 30-day commercial paper rate as
published in the Wall Street Journal plus 265 basis points (8.04% at July 31,
1996). The Agreement is collateralized by substantially all of the Company's
assets and general intangibles. Financial covenants under the Agreement require
the Company to maintain certain levels of tangible net worth and debt to net
worth ratios and limits capital expenditures in any one fiscal year to $5
million. On August 15, 1996, the Agreement was extended through December 31,
1996 with the same terms and conditions in anticipation of the previously
announced merger with Brunswick Biomedical Corporation ("BBC"). Upon
consummation of this merger, proceeds from a newly established $5 million line
of credit will become immediately available for repayment of the MLBFS note
payable. If the merger with BBC is not consummated, the Company will seek a
renewal of the Agreement or an alternative source of financing. There can be
no assurance that any such alternative source of financing will be available on
terms favorable to the Company.
The merger would subject the Company to the financial commitments of BBC which
currently include an $11 million bridge loan that will be converted to a $10
million long-term loan upon completion of the merger. The long-term loan
contains covenants which are applicable to the financial condition of the merged
Company. In order to adequately service the long-term loan and comply with the
financial covenants, the merged Company must achieve significantly higher
operating results, obtain external financing from strategic partners interested
in its R&D programs and/or obtain additional equity financing. At this time,
there is no assurance that the merger will occur, and, if the merger does occur,
that the Company will comply with the financial covenants of the long-term loan.
Over the last five fiscal years, the Company has expended more than $15 million
for capital equipment designed to expand production capacity to accommodate
commercial sales growth. Partial proceeds from a $5.4 million secured loan
agreement with Syntex were used to finance a portion of this capital program.
Principal repayments commenced August 1, 1991 through credits against amounts
invoiced to Syntex for product delivered under a related Manufacturing and
Packaging Agreement. As part of the termination of this agreement, the
repayment terms of the loan agreement were modified to include an eighteen-month
moratorium on the repayment of principal beginning with the calendar quarter
ended March 31, 1993 through the calendar quarter ended June 30, 1994.
23
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (CONTINUED)
Principal payments to Syntex resumed for the calendar quarter ended September
30, 1994 at the minimum of $200,000 per quarter reducing the outstanding loan
balance $800,000 during fiscal 1996 to $588,400 at July 31, 1996. The loan
bears interest at the same rate the Company pays on its current line of credit
facility. Interest expense recognized on this loan totalled
$86,000 in fiscal 1996. The loan is subject to acceleration upon the occurrence
of certain events. See Note 7 in Notes to Consolidated Financial Statements.
The Company has significant capital needs which will need to be funded
externally in order to finance its plans to automate many of the Company's
aseptic filling, assembly and final packaging processes. During fiscal 1996,
the Company began to purchase high-speed, drug cartridge preparation and filling
equipment as well as automated assembly and packaging equipment. This equipment
will not only increase efficiency and capacity while improving profit margins,
but it will also result in less human contact with products during the
manufacturing process. Finally, as part of STI's new product development
efforts, the Company must purchase high cavitation molds for its new automatic
injection devices which will also require external funding.
To assist in financing the capital investment program mentioned above, the
Company entered into a loan agreement with The CIT Group/Equipment Financing,
Inc. ("CIT") in May 1995. This arrangement consists of a series of loans for the
acquisition of production molds, high speed component preparation and filling
equipment and facility renovations not to exceed a maximum aggregate of $3
million. Additional terms include repayment of each loan in sixty (60) equal
monthly installments at a fixed interest rate equal to the Treasury Yield (as
published in the Wall Street Journal two business days prior to closing a loan
amount) plus 247 basis points. Loan proceeds to date totalled $1.5 million with
a loan balance outstanding of $1.2 million at July 31, 1996 with a weighted
average interest rate of 8.8%. See Note 7 in Notes to Consolidated Financial
Statements.
BALANCE SHEET REVIEW
Working capital increased $539,900 (15%) to $4,204,200 at July 31, 1996 from
$3,668,300 at July 31, 1995. Receivables increased $1.5 million (25%) on the
strength of higher EpiPen and Diazepam auto-injector sales. Inventory levels
increased $1.1 million (30%) in support of higher sales levels anticipated for
the first quarter of fiscal 1997 when compared with the first quarter of fiscal
1996. These sales will include new products introduced earlier in fiscal 1996,
the EpiE-ZPen and the Diazepam auto-injectors. Prepaid expenses and other
current assets increased $416,300 resulting in the prepayment to the FDA for
annual user fees. The deferred income tax asset increased $186,600 (18%) due to
an increase in expenses related to the restructuring plan initiated in fiscal
1995.
Note payable to bank remained constant at $3.9 million from fiscal 1995 to
fiscal 1996 while accounts payable increased $1.2 million (120%) resulting from
the acquisition of inventory components in support of fiscal 1997 sales as
discussed above. Proceeds from operations during fiscal 1996 contributed to the
funding necessary to make scheduled quarterly payments to Syntex which reduced
the note payable to Syntex by $800,000 (58%) to $588,400 at July 31, 1996. See
"Liquidity and Capital Resources" above. The increase in customer deposits
($703,500) represents an upfront payment for continuing development work to be
completed in fiscal 1997. Other liabilities and accrued expenses increased
$436,000 (37%) due to a higher
24
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS (CONTINUED)
accrual for income taxes payable. The restructuring reserve increased $190,400
(42%), net of employee severance payments associated with the previously
discussed organizational changes.
Other long-term debt, including the current portion, increased $311,300 (22%)
due to a non-interest bearing note from Center in the amount of $375,000 to
assist in the cost reduction program associated with the EpiE-ZPen. This loan
will be repaid to Center through credits on future EpiE-ZPen deliveries
commencing in September 1996. Additional proceeds under the CIT loan agreement
were more than offset by payments made on the initial CIT loan (see "Liquidity
and Capital Resources") and capital lease obligations. Deferred revenue
decreased $250,000 (100%) with the recognition of the remaining revenue of a
development contract which was closed-out during the first quarter.
Capital expenditures totalled $2.3 million in fiscal 1996 which consisted
primarily of improvements designed to automate and validate current production
processes at the Company's St. Louis manufacturing facility. The timing of
capital expenditures to keep pace with prior year levels is contingent on the
Company's ability to identify outside sources of capital. Shareholder's equity
increased $1.3 million on the strength of net income ($1.28 million) and from
the exercise of employee stock options.
INFLATION AND ACCOUNTING POLICIES
In the view of management, the low levels of inflation in recent years and
changing prices have had no significant effect on the Company's financial
condition and results of operations. Generally, the Company is able to mitigate
the effects of inflation on operating costs and expenses through price increases
and productivity gains.
The Company applies the intrinsic value method of accounting prescribed by APB
Opinion No. 25, "Accounting for Stock Issued to Employees" in accounting for its
stock-based compensation. Accordingly, the Company has not recognized any
compensation associated with fair value accounting. Beginning in fiscal 1997,
the Company will be required to make certain additional disclosures as if the
fair value method of accounting defined in SFAS 123, "Accounting for Stock-Based
Compensation" had been applied to the Company's stock option plans.
25
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
CONSOLIDATED BALANCE SHEETS
SURVIVAL TECHNOLOGY, INC.
- ----------------------------------------------------------------------------------------
July 31 1996 1995
- ----------------------------------------------------------------------------------------
ASSETS
Current assets:
Cash $ 122,800 $ 503,600
Receivables, less allowance for doubtful
accounts of $45,000 and $13,000 7,332,300 5,852,700
Inventories 4,988,800 3,829,800
Prepaid expenses and other assets 752,400 336,100
Deferred income taxes 1,217,500 1,030,900
----------- -----------
Total current assets 14,413,800 11,553,100
----------- -----------
Fixed assets:
Furniture and equipment 17,696,500 15,389,000
Leasehold improvements 6,726,800 5,619,800
Construction in progress 2,124,100 3,572,500
----------- -----------
26,547,400 24,581,300
Less accumulated depreciation and amortization 11,732,400 10,372,400
----------- -----------
14,815,000 14,208,900
----------- -----------
Patents and licenses, at cost less amortization
of $675,100 and $517,200 1,848,400 1,916,800
Other noncurrent assets 7,800 36,300
----------- -----------
$31,085,000 $27,715,100
----------- -----------
----------- -----------
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Note payable to bank $ 3,875,400 $ 3,917,000
Note payable to Syntex 588,400 800,000
Current portion of long-term debt 516,800 492,600
Accounts payable 2,240,700 1,016,800
Customer deposits 736,000 32,500
Restructuring reserve 640,400 450,000
Other liabilities and accrued expenses 1,611,900 1,175,900
----------- -----------
Total current liabilities 10,209,600 7,884,800
Long-term debt:
Note payable to Syntex 588,400
Other long-term debt 1,184,300 897,200
Deferred revenue 250,000
Other noncurrent liabilities 616,500 489,200
Deferred income taxes 1,605,500 1,455,000
----------- -----------
Total liabilities 13,615,900 11,564,600
----------- -----------
Commitments and contingencies
Shareholders' equity:
Common stock $.10 par value; 10,000,000
shares authorized; 3,091,700 and
3,085,400 shares issued and outstanding 309,100 308,500
Paid-in capital in excess of par value 5,114,700 5,072,700
Retained earnings 12,045,300 10,769,300
----------- -----------
Total shareholders' equity 17,469,100 16,150,500
----------- -----------
$31,085,000 $27,715,100
----------- -----------
----------- -----------
See Notes to Consolidated Financial Statements.
26
CONSOLIDATED STATEMENTS OF INCOME
SURVIVAL TECHNOLOGY, INC.
- ----------------------------------------------------------------------------------------------------------
Year Ended July 31 1996 1995 1994
- ----------------------------------------------------------------------------------------------------------
Net sales $31,385,300 $25,486,800 $24,856,500
Cost of sales 22,428,200 17,227,500 16,199,600
----------- ----------- -----------
Gross profit 8,957,100 8,259,300 8,656,900
----------- ----------- -----------
Selling, general, and
administrative expenses 3,881,600 4,171,500 4,469,800
Research and development expenses 606,600 943,000 1,024,600
Depreciation and amortization expenses 1,873,300 1,805,000 1,234,900
Restructuring charge 321,900 450,000
----------- ----------- -----------
6,683,400 7,369,500 6,729,300
----------- ----------- -----------
Operating income 2,273,700 889,800 1,927,600
----------- ----------- -----------
Other income (expense):
Interest expense (387,200) (372,900) (70,600)
Other income (expense), net 87,600 193,200 151,200
Gain on sale of Medical Device Division 1,562,300
----------- ----------- -----------
(299,600) (179,700) 1,642,900
----------- ----------- -----------
Income before income taxes 1,974,100 710,100 3,570,500
Provision for income taxes 698,100 249,600 1,442,000
----------- ----------- -----------
Net income $ 1,276,000 $ 460,500 $ 2,128,500
----------- ----------- -----------
----------- ----------- -----------
Per common share:
Net income $.41 $ .15 $ .68
----------- ----------- -----------
----------- ----------- -----------
See Notes to Consolidated Financial Statements.
27
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
SURVIVAL TECHNOLOGY, INC.
Paid-in
Common Stock Capital in
------------ Excess of Retained
Shares Amount Par Value Earnings Total
- -------------------------------------------------------------------------------------------------------------------
Balance at July 31, 1993 3,085,000 $308,500 $5,068,900 $8,180,300 $13,557,700
1994 net income 2,128,500 2,128,500
Exercise of stock options 400 3,800 3,800
--------- --------- ---------- ----------- -----------
Balance at July 31, 1994 3,085,400 308,500 5,072,700 10,308,800 15,690,000
1995 net income 460,500 460,500
--------- --------- ---------- ----------- -----------
Balance at July 31, 1995 3,085,400 308,500 5,072,700 10,769,300 16,150,500
1996 net income 1,276,000 1,276,000
Exercise of stock options 6,300 600 42,000 42,600
--------- --------- ---------- ----------- -----------
Balance at July 31, 1996 3,091,700 $ 309,100 $5,114,700 $12,045,300 $17,469,100
--------- --------- ---------- ----------- -----------
--------- --------- ---------- ----------- -----------
See Notes to Consolidated Financial Statements.
28
CONSOLIDATED STATEMENTS OF CASH FLOWS
SURVIVAL TECHNOLOGY, INC.
Year Ended July 31, 1996 1995 1994
- ----------------------------------------------------------------------------------------------------------
Cash flows from operating activities:
Net income $ 1,276,000 $ 460,500 $ 2,128,500
Adjustments to reconcile net income
to net cash provided by (used for)
operating activities net of effects from
sale of Medical Device Division in 1994:
Depreciation and amortization 1,873,300 1,805,000 1,234,900
Gain on sale of Medical Device Division (1,562,300)
Loss (gain) on equipment disposals 800 (63,500)
Deferred income taxes (36,100) 32,800 660,300
Deferred lease incentives (30,200) (30,200) 16,800
(Increase) decrease in receivables (1,479,600) 83,600 (805,800)
Increase in inventories (1,159,000) (1,034,500) (230,800)
(Increase) decrease in prepaid
expenses and other assets (416,300) 216,700 (35,600)
Increase (decrease) in accounts payable 1,223,900 (313,600) (141,300)
Increase (decrease) in customer deposits 703,500 (33,800) (161,800)
(Decrease) increase in deferred revenue (250,000) 250,000
Increase in restructuring reserve 190,400 450,000
Increase in other liabilities and
accrued expenses 593,500 154,000 476,600
----------- ----------- -----------
Net cash provided by operating activities 2,490,200 1,790,500 1,766,000
----------- ----------- -----------
Cash flows from investing activities:
Purchases of fixed assets (2,338,100) (3,797,800) (3,172,800)
Purchases of patents and licenses (89,500) (199,900) (184,800)
Proceeds from fixed asset dispositions 38,700
Decrease (increase) in other noncurrent assets 5,500 34,200 (38,200)
----------- ----------- -----------
Net cash used for investing activities (2,383,400) (3,963,500) (3,395,800)
----------- ----------- -----------
Cash flows from financing activities:
Net (payments) proceeds on note
payable to bank (41,600) 2,612,500 1,704,500
Payments on note payable to Syntex (800,000) (800,000)
Proceeds from other long-term debt 820,300 1,299,300
Payments on other long-term debt (508,900) (500,200) (288,200)
Proceeds from issuance of common stock 42,600 3,800
----------- ----------- -----------
Net cash (used for) provided by financing activities (487,600) 2,611,600 1,420,100
----------- ----------- -----------
Net (decrease) increase in cash (380,800) 438,600 (209,700)
Cash at beginning of year 503,600 65,000 274,700
----------- ----------- -----------
Cash at end of year $ 122,800 $ 503,600 $ 65,000
----------- ----------- -----------
----------- ----------- -----------
Cash paid for interest $ 526,100 $ 514,300 $ 189,800
----------- ----------- -----------
----------- ----------- -----------
Cash paid for income taxes $ 513,300 $ 234,300 $ 807,200
----------- ----------- -----------
----------- ----------- -----------
See Notes to Consolidated Financial Statements.
29
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SURVIVAL TECHNOLOGY, INC.
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Survival Technology, Inc. ("Company") is a technology-based health care company
that designs, develops and produces a broad range of automatic injectors,
prefilled syringes and other innovative health care devices, with a major focus
on safe and convenient participation by the patient in injection therapy. The
Company also supplies customized drug delivery system design, pharmaceutical
research and development and GMP-approved sterile product manufacturing to
pharmaceutical and biotechnology companies.
PRINCIPLES OF CONSOLIDATION
The consolidated financial statements include the accounts of Survival
Technology, Inc. and its wholly owned subsidiaries ("Company"). All
intercompany accounts and transactions are eliminated in consolidation.
INVENTORIES
Inventories relating to commercial and military products are stated at the lower
of cost (first-in, first-out) or market.
FIXED ASSETS AND DEPRECIATION
Fixed assets are stated at cost. The Company computes depreciation and
amortization under straight-line and accelerated methods using the following
estimated useful lives:
Furniture and equipment 2 to 15 years
Capital leases and leasehold improvements 4 to 20 years
In addition, the Company uses either the units of production method or the
straight line method over a 10-year life (whichever period is shorter) to
depreciate production molds and tooling over their estimated production life
cycle. Major additions and improvements including validation costs are
capitalized and ordinary repairs, maintenance, and renewals are expensed in the
year incurred. Gains or losses on the sale or retirement of fixed assets result
from the difference between sales proceeds and the assets' net book value.
PATENTS AND LICENSES
Legal costs incurred in connection with patent applications and costs of
acquiring patents and licenses are capitalized and amortized on a straight-line
basis over the life of the patent (not to exceed seventeen years) or license or
over the period expected to be benefitted, principally over 5 to 20 years.
REVENUE RECOGNITION
Sales of medical products are recorded when shipments are made to customers.
Revenues from the U.S. Department of Defense ("DoD") industrial base maintenance
contract are recorded ratably throughout the contract term with the exception of
revenue from the component prestocking program that is recorded upon component
receipt in STI's warehouse and product
30
sales which are recorded upon shipment to the customer. Revenues from license
fees are recorded when the fees are due and non-refundable. Revenues from
research and development arrangements are recognized in the period in which
related work has been substantially completed.
RESEARCH AND DEVELOPMENT
Research and development expenses are charged to operations in the period
incurred.
INCOME TAXES
The Company accounts for taxes using the asset and liability approach as
prescribed by Statement of Financial Accounting Standards No. 109 ("SFAS 109"),
"Accounting for Income Taxes". The asset and liability approach requires the
recognition of deferred tax assets and liabilities for expected future tax
consequences of temporary differences between carrying amounts and tax basis of
assets and liabilities.
FINANCIAL INSTRUMENTS
The estimated fair value of the Company's financial instruments, which include
cash, receivables, notes payable and current/long-term debt, approximates their
carrying value.
USE OF ESTIMATES AND ASSUMPTIONS
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenue and expenses during the reporting period.
Actual results could differ from those estimates and assumptions.
NET INCOME PER COMMON SHARE
Net income per common share is computed on the weighted average number of common
and common equivalent shares outstanding which were as follows: 3,116,700 in
1996, 3,102,500 in 1995 and 3,117,600 in 1994. Stock options are considered to
be common equivalent shares when dilutive.
RECLASSIFICATION
Certain reclassifications have been made to prior year financial statements in
order to conform with the current year presentation.
31
2. INVENTORIES
Inventories are comprised of the following:
July 31 1996 1995
- ------- ---- ----
Components and subassemblies $2,968,600 $2,780,200
Labor and overhead costs in process 1,401,900 605,100
Finished goods 1,055,800 674,800
---------- ----------
5,426,300 4,060,100
Inventory reserve (437,500) (230,300)
---------- ----------
$4,988,800 $3,829,800
---------- ----------
---------- ----------
Inventories do not include amounts related to the DoD component prestocking
program which are segregated in STI's warehouse facilities for future DoD
contract requirements.
3. RESTRUCTURING CHARGE
In fiscal 1995, a restructuring plan was approved by the Company's Board of
Directors resulting in a $450,000 charge against earnings for the relocation of
its corporate office. As part of this plan, the Company initiated certain
organizational changes during fiscal 1996 resulting in additional charges
related to severance benefits provided to certain employees terminated during
fiscal 1996.
The following table sets forth the Company's restructuring charges for the year
ended July 31, 1996 and 1995:
Loss From Restructuring of Operations
-------------------------------------
1996 1995
Corporate:
Employee severance accrued $ 321,900 0
Relocation of facilities 0 $ 450,000
--------- ---------
$ 321,900 $ 450,000
--------- ---------
--------- ---------
The following table sets forth the Company's restructuring reserve as of
July 31, 1996:
Restructuring Reserve
---------------------
Relocation Employee
of facilities Separations Total
------------- ----------- -----
Reserve as of July 31, 1995 $ 450,000 $ 450,000
Restructuring of operations 321,900 321,900
Cash payments (7,200) (124,300) (131,500)
--------- --------- ---------
Reserve as of July 31, 1996 $ 442,800 $ 197,600 $ 640,400
--------- --------- ---------
--------- --------- ---------
In October 1996, the Company signed a letter of intent to sublease its corporate
office space in Rockville, Maryland and entered into a new lease in Columbia,
Maryland for the relocation of the corporate headquarters. The reserve balance
for the relocation of facilities at July 31, 1996 is sufficient to cover both
the moving costs and the lease rate differential on the sublease. The Company
is scheduled to move its corporate headquarters by December 1996.
32
4. MERGER WITH BRUNSWICK BIOMEDICAL CORPORATION
On April 15, 1996, Brunswick Biomedical Corporation ("BBC"), a privately-held
medical device company, purchased 61.1% of the Company's outstanding common
stock from the estate of the Company's late founder, Dr. Stanley J. Sarnoff.
On September 11, 1996, the Company and BBC entered an Agreement and a Plan of
Merger ("Merger Agreement"). Pursuant to the Merger Agreement, each outstanding
share of BBC's common stock will be exchanged for 2.1 shares of the Company's
common stock and the Company's common stock will remain outstanding. Each of
BBC's outstanding shares of preferred stock will be converted into a right to
receive 2.1 shares of the Company's common stock and a warrant to purchase 0.4
share of the Company's common stock at an exercise price of $11.00 per share,
exercisable for a period of five years following the merger. In addition, the
Company will assume BBC's obligations under outstanding options and warrants.
These provisions of the agreement will result in 1,708,928 shares of the
Company's common stock being issued in exchange for BBC stock at the time of the
merger and could result in the issuance of an additional 1,053,358 shares of the
Company's common stock if all options and warrants were exercised and the
required consideration paid. Each of the 1,888,126 shares of Company's common
stock currently owned by BBC will be retired in the merger. The transaction
requires approval by both the Company's and BBC's shareholders and is expected
to be completed during the second quarter of fiscal 1997.
The merger would subject the Company to the financial commitments of BBC which
currently include an $11 million bridge loan that will be converted to a $10
million long-term loan upon completion of the merger. The long-term loan
contains covenants which are applicable to the financial condition of the merged
Company. In order to adequately service the long-term loan and comply with the
financial covenants, the merged Company must achieve significantly higher
operating results, obtain external financing from strategic partners interested
in its R&D programs and/or obtain additional equity financing. At this time,
there is no assurance that the merger will occur, and, if the merger does occur,
that the Company will comply with the financial covenants of the long-term loan.
Pursuant to the Merger Agreement, BBC will be merged into the Company, the
existence of BBC will cease, and the Company, as the surviving corporation, will
continue to exist. Although the Company will be the surviving corporation in
the merger as a legal matter, the merger will be treated as a purchase of the
Company by BBC for accounting purposes. As a result, the Company's assets and
liabilities, revalued to their respective fair values, and BBC's historical
financial statements will reflect the combined operation of the Company and
Brunswick after the effective date of the merger.
33
The following unaudited pro forma financial information reflects the adjustment
of the historical financial information to give effect to the merger as if the
merger transaction occurred on August 1, 1995.
Statement of Operations for the year ended July, 31, 1996:
- ----------------------------------------------------------
Total revenue $35,014,900
Cost of sales 24,408,600
-----------
Gross profit 10,606,300
Operating expenses * 15,421,700
-----------
Operating loss (4,815,400)
Non-operating expenses 1,985,200
Provision for income taxes 100,000
-----------
Net loss $(6,900,600)
-----------
-----------
Net loss per share $(2.09)
------
------
* Included in operating expenses is a non-recurring write-off of in-process
research and development totalling $4.5 million.
Balance sheet at July, 31, 1996:
- --------------------------------
Current assets $16,351,100
Property, plant and equipment 14,743,500
Other assets 13,354,900
-----------
Total assets $44,449,500
-----------
-----------
Current liabilities $12,723,900
Long-term debt 16,089,400
Other liabilities 2,222,000
Total stockholders' equity 13,414,200
-----------
Total liabilities and shareholders' equity $44,449,500
-----------
-----------
5. SALE OF MEDICAL DEVICE DIVISION
On July 31, 1994, the Company sold substantially all of the assets (exclusive of
trade receivables) and the business of its Medical Device Division ("MDD") to
Brunswick Biomedical Corporation ("BBC") of Marlboro, Massachusetts. The MDD
designed, manufactured and marketed electronic heart monitoring devices known as
CardioBeeper-Registered Trademark- ECG transmitters ("CardioBeepers"). James H.
Miller, president, chief executive officer and director of the Company also is
chairman, president, chief executive officer and a shareholder of BBC.
The assets sold consisted primarily of business equipment, inventories of
CardioBeepers and related components, patents and customer account lists. In
consideration of the asset purchase, BBC paid the Company $2 million in cash at
the closing date with future payments not to exceed $1 million based on net
sales of the Division over the next five years. The proceeds of the sale ($2
million) were used to reduce current bank borrowings at July 31, 1994. Royalty
payments in fiscal 1996 and 1995 aggregated $90,000 and $133,400, respectively.
At July 31, 1996, royalty payments of $59,600 were outstanding and unpaid.
34
This sale was recorded by the Company in the fourth quarter of its fiscal year
ended July 31, 1994 resulting in a non-recurring pretax gain on disposal of
$1,562,300 which includes a provision for costs associated with the sale,
including employee severance costs and legal expenses. This nonrecurring gain
is exclusive of potential future payments. Revenues generated from this
division in fiscal 1994 were $1.9 million.
6. ACQUISITION OF MEDIMECH ASSETS
On November 18, 1992, the Company acquired the principal assets of Medimech
International Limited ("Medimech"), a designer and manufacturer of auto-
injectors based in the United Kingdom for $1,524,200 in cash. In addition, the
Company will be required to make future payments for an eight-year period equal
to 7.5% of the net sales of Medimech products after such sales exceed $3
million. There have been no additional payments made through July 31, 1996.
The acquisition was accounted for as a purchase.
The purchase of Medimech was financed in part through an arrangement with E.M.
Industries, Inc. ("EMI"), whose division, Center Laboratories, Inc. ("Center"),
is the Company's exclusive distributor of EpiPen-Registered Trademark- auto-
injectors. EMI provided $1.2 million to the Company in exchange for: 61,900
shares of the Company's common stock, a license fee totalling $300,000 for the
exclusive marketing rights to certain future products under agreements to be
negotiated and a $300,000 non-interest bearing loan to be repaid through credits
on future sales of EpiPen auto-injectors by the Company to Center commencing
January 1, 1993. The loan was paid off in fiscal 1995. The balance of the
purchase price was financed by the Company through internal sources.
7. DEBT ACTIVITY
NOTE PAYABLE TO BANK
The Company has a revolving credit agreement ("Agreement") with Merrill Lynch
Business Financial Services, Inc. ("MLBFS") with a maximum commitment of $5
million. Outstanding borrowings under the Agreement totalled $3.9 million at
July 31, 1996 and 1995, respectively, with an interest rate equal to the 30-day
commercial paper rate as published in the Wall Street Journal plus 265 basis
points (8.04% at July 31, 1996 and 8.48% at July 31, 1995.) The agreement is
collateralized by substantially all of the Company's assets and general
intangibles. Financial covenants under the Agreement require the Company to
maintain certain levels of tangible net worth and debt to net worth ratios while
limiting capital expenditures to no more than $5 million in any one fiscal year.
During the first quarter of fiscal 1997, the Agreement was extended through
December 1996 with the same terms and conditions.
NOTE PAYABLE TO SYNTEX
On April 16, 1991, the Company signed a Loan Agreement (the "Loan Agreement")
pursuant to which Syntex Laboratories, Inc. ("Syntex") of Palo Alto, California
agreed to lend $5.4 million to the Company. Approximately $2.9 million of the
loan proceeds were used to finance capital expenditures with the balance of $2.5
million to finance working capital requirements. The Company drew down on the
capital expenditure portion of the Loan Agreement as equipment was purchased.
Principal repayments commenced August 1, 1991 through credits against amounts
invoiced to Syntex for product delivered under a Manufacturing and Packaging
Agreement between the parties.
35
On November 30, 1992, the Company and Syntex agreed to terminate the
Manufacturing and Packaging Agreement effective February 15, 1993. As part of
this termination agreement, the repayment terms of the Loan Agreement were
modified to include an eighteen-month moratorium on the repayment of principal
beginning with the calendar quarter ended March 31, 1993 through the calendar
quarter ended June 30, 1994. The outstanding loan balance (approximately $2.2
million) was non-interest bearing from January 1, 1993 through June 30, 1994 and
effective July 1, 1994 began bearing interest at a rate equal to that which the
Company pays on its current commercial line of credit facility. Principal
payments resumed for the calendar quarter ended September 30, 1994 at the
minimum of $200,000 per quarter and aggregated $800,000 in both fiscal 1996 and
1995. The loan is subject to acceleration upon the occurrence of certain
events.
The Loan Agreement is collateralized by approximately $6.5 million of existing
equipment and general intangibles. Any security interest that Syntex may have
on newly acquired equipment by the Company and all proceeds thereof is subject
and subordinate to the security interest of MLBFS.
OTHER LONG-TERM DEBT
On May 23, 1995, the Company entered into a loan agreement with The CIT
Group/Equipment Financing, Inc. ("CIT") to assist in financing the Company's
capital investment programs. This arrangement will consist of a series of loans
for the acquisition of production molds, high speed component preparation and
filling equipment and facility renovations not to exceed a maximum aggregate of
$3 million. Loan proceeds totalled $445,300 and $1,046,100 in fiscal 1996 and
1995, respectively, of which $1.2 million was outstanding at July 31, 1996 with
an interest rate of 8.8%. Terms include repayment of each loan in sixty (60)
equal monthly installments at a fixed interest rate equal to the Treasury Yield
(as published in the Wall Street Journal two business days prior to closing on a
loan amount) plus 247 basis points. The agreement with CIT is collateralized by
the assets financed with the loan proceeds. CIT's security interest in such
assets is subject and subordinate to the security interest of Syntex.
On January 11, 1996, the Company received a non-interest bearing loan in the
amount of $375,000 from Center Laboratories, Inc. ("Center"), STI's exclusive
distributor for the EpiPen and EpiE-ZPen. The proceeds from this loan will
assist the Company in purchasing high-speed filling and automated packaging
equipment which will reduce the cost of manufacturing the EpiE-ZPen. Repayment
of this loan will commence during the first quarter of fiscal 1997 with an
agreed upon credit per unit on EpiE-ZPen shipments to Center. The Company
anticipates loan repayment to be completed in fiscal 1999.
Other long-term debt consisted of the following:
July 31 1996 1995
- ------- ------ ------
CIT Group/Equipment Financing, Inc. $1,209,100 $ 996,600
Capital lease obligations (See Note 11) 117,100 393,200
Note payable to Center, non-interest bearing 375,000
---------- ---------
1,701,200 1,389,800
Less current portion 516,800 492,600
---------- ---------
Other long-term debt $1,184,400 $ 897,200
---------- ---------
---------- ---------
36
Minimum annual principal payments on other long-term debt, exclusive of
capitalized lease obligations, are as follows: 1997 - $417,100; 1998 -
$477,500; 1999 - $374,900; 2000 - $287,900; 2001 - $26,700. Capitalized
interest costs in fiscal 1996, 1995 and 1994 totalled $132,400, $137,700, and
$130,100, respectively.
8. STOCK OPTION PLANS
The Company has adopted two Stock Option Plans ("the Plans") which reserve
700,000 shares for the granting of options through 2001 and provide for issuance
of non-qualified stock options, incentive stock options, stock appreciation
rights, incentive shares and restricted stock.
Options granted to employees, officers and directors pursuant to the Company's
stock option plans generally have been exercisable in varying amounts in
cumulative annual installments up to ten years from the date of grant. The
exercise price on all options granted during the three years ended July 31, 1996
was equivalent to the market value of the Company's stock on the date of grant.
At July 31, 1996, there were no stock appreciation rights outstanding.
The following table summarizes the activity in the Company's stock options
during fiscal 1996, 1995 and 1994:
Number of Shares 1996 1995 1994
- ---------------- ------ ------ ------
Options outstanding
at beginning of year 305,000 269,200 169,400
Granted during the year 36,900 60,100 109,700
Exercised during the year (6,200) 0 (400)
Expired or terminated
during the year (41,900) (24,300) (9,500)
------- ------- -------
Options outstanding
at end of year
Number of shares 293,800 305,000 269,200
Price per share $6.75-20.75 $6.75-20.75 $6.75-20.75
Aggregate price $3,011,400 $3,205,300 $3,032,800
Options reserved for
granting at end of year 106,800 109,100 156,000
Options exercised
during the year
Number of shares 6,200 none 375
Price per share $6.75-8.75 $10.125
Aggregate price $42,600 $3,800
Fair value per share $8.00-11.51 $12.75
Aggregate fair value $61,400 $4,800
Options exercisable
at end of year 196,800 176,100 118,600
The Estate of Stanley J. Sarnoff, the Company's late founder, holds options to
purchase up to 32,500 shares of the Company's common stock through September 14,
2000 (as to 30,000 shares) and 2003 (as to 2,500 shares) at a price of $9.875
and $10.78, respectively. The Company is obligated under certain circumstances
to register, under the Securities Act of 1933, shares of the Company's stock
owned by the Estate.
During the first quarter of fiscal 1997, an executive officer was granted an
option to purchase 40,000 shares of the Company's common stock at an exercise
price equal to its fair market value ($9.50). Under the terms of the grant, the
option is exercisable as to 10,000 common stock shares six months after the date
of grant and will vest with respect to the remaining 30,000 shares in one-third
annual increments. In addition, the vesting of such 30,000 shares wil1 be
accelerated, in 10,000 share increments, if the market price for the common
stock reaches $18.00, $27.00 and $36.00, respectively.
37
9. INCOME TAXES
As discussed in Note 1, the Company records income taxes using the asset and
liability approach as prescribed by SFAS 109, "Accounting for Income Taxes."
The asset and liability approach requires the recognition of deferred tax
liabilities and assets for the expected future tax consequences of temporary
differences between the carrying amounts and the tax basis of other assets and
liabilities.
The provision (benefit) for income taxes in fiscal 1996, 1995 and 1994 consists
of:
Year Ended July 31 1996 1995 1994
------------------ ---------- ---------- ----------
Current:
Federal $ 618,300 $ 220,000 $ 603,100
State 115,900 (3,200) 178,600
---------- ---------- ----------
734,200 216,800 781,700
---------- ---------- ----------
Deferred:
Federal (29,500) 26,900 588,200
State ( 6,600) 5,900 72,100
---------- ---------- ----------
(36,100) 32,800 660,300
---------- ---------- ----------
$ 698,100 $ 249,600 $1,442,000
---------- ---------- ----------
---------- ---------- ----------
The Company provides deferred taxes for temporary differences between the book
basis of assets and liabilities for financial reporting purposes and the book
basis of assets and liabilities for tax return purposes. The net deferred tax
liability is attributable to the following:
July 31 1996 1995
------- ----------- -----------
Inventory valuation $ 255,600 $ 175,700
Uniform inventory capitalization 322,300 370,300
Postretirement benefits 173,700 112,900
Deferred lease income 64,200 75,900
Vacation expenses 57,900 57,900
Restructuring charge 247,200 173,700
Other 96,600 64,500
------------ -----------
Gross deferred tax asset 1,217,500 1,030,900
------------ -----------
Depreciation (1,492,700) (1,370,400)
Patent costs (112,800) (77,200)
Other (7,400)
------------ -----------
Gross deferred tax liability $ (1,605,500) (1,455,000)
------------ -----------
Net deferred tax liability $ (388,000) $ (424,100)
------------ -----------
------------ -----------
A reconciliation of the effective tax rate for fiscal 1996, 1995 and 1994 to the
U.S. Federal income tax rate is provided in the following tabulation:
Year Ended July 31 1996 1995 1994
------------------ ---- ---- ----
Statutory Federal tax rate 34.0% 34.0% 34.0%
State taxes, net of Federal
tax benefit 4.6% 4.6% 4.6%
Other (3.2%) (3.5%) 1.8%
---- ---- ----
Effective income tax rate 35.4% 35.1% 40.4%
---- ---- ----
---- ---- ----
38
10. EMPLOYEE RETIREMENT PLANS
PENSION AND SAVINGS PLANS
The Company maintains a profit sharing thrift plan covering all full-time
employees not covered by a collective bargaining agreement. Annual
contributions by the Company under the plan may be made on the basis of
available retained earnings up to 6.6% of the base annual salary of all plan
participants. Plan benefit allocations are based on the participants' average
annual compensation. The Company made no contributions in fiscal 1996 while
contributing $50,000 and $75,000 in fiscal 1995 and 1994, respectively. As part
of this profit sharing thrift plan, eligible employees may elect to contribute
up to 12% of their base annual salary to the plan. The Company matches a
portion of employee contributions which amounted to $172,000, $161,000 and
$129,100 in fiscal 1996, 1995 and 1994, respectively.
The Company also made payments to pension plans for its full-time employees in
St. Louis, Missouri covered by a collective bargaining agreement. Contributions
to this plan aggregated $78,900, $72,900 and $76,900 in fiscal 1996, 1995 and
1994, respectively.
OTHER POSTRETIREMENT BENEFITS
The Company sponsors a postretirement benefit plan ("the Plan") to provide
certain medical and life insurance benefits to retirees, their spouses and
dependents. Employees terminated from active service after March 1992 who are
at least 60 years of age but no more than age 65, with 20 years service, are
eligible for medical coverage. Employees who terminated from active service
prior to April 1, 1992 who were at least 55 years of age, but no more than age
65, with 10 years service, are eligible for medical and life insurance coverage.
Upon reaching age 65, Medicare becomes the retiree's primary medical coverage.
The Plan is contributory for medical benefits based on the retiree's years of
service and noncontributory for life insurance benefits.
On August 1, 1993, the Company adopted Statement of Financial Accounting
Standard No. 106 "Employee's Accounting of Postretirement Benefits Other Than
Pension" ("SFAS 106"). The Company had previously recorded the expense
associated with these benefits on a pay-as-you-go basis. Under SFAS 106, the
cost of providing retiree health care and life insurance benefits is actuarially
determined and accrued over the service period of an employee. The unrecognized
transition obligation upon adoption of the standard on August 1, 1993, was
$898,000. The Company has elected to amortize the transition obligation on a
straight-line basis over a twenty-year period.
The following table sets forth the Plan's funded status reconciled with the
amount included in deferred compensation in the balance sheet:
July 31 1996 1995 1994
- ------- ---- ----- ----
Accumulated postretirement benefit obligation:
Retirees $ 877,000 $ 665,000 $ 234,000
Fully eligible and other Plan participants 502,000 554,000 775,000
---------- ---------- ----------
1,379,000 1,219,000 1,009,000
Unrecognized prior service cost (60,000)
Unrecognized net loss (107,000) (98,000)
Unrecognized transition obligation (762,000) (808,000) (852,700)
---------- ---------- ----------
Accrued postretirement benefit cost $ 450,000 $ 313,000 $ 156,300
---------- ---------- ----------
---------- ---------- ----------
39
In fiscal year 1995, the Plan incurred an unrecognized net loss of $105,000,
which the Company has elected to amortize on a straight-line basis over a
fifteen-year period.
Net periodic postretirement benefit cost included the following:
Year ended July 31 1996 1995 1994
- ------------------ ------ ------ ------
Service cost-benefits attributed to service
during periods $ 53,000 $ 66,000 $ 55,000
Interest cost on accumulated postretirement
benefit obligation 100,000 85,000 76,000
Amortization of net loss 7,000
Amortization of transition obligation 45,000 45,000 45,000
-------- -------- --------
Net periodic postretirement benefit cost $205,000 $196,000 $176,000
-------- -------- --------
-------- -------- --------
For measurement purposes, a 9.5% annual rate of increase in cost of health care
was assumed for fiscal 1996; the rate was assumed to decrease gradually to 5% by
2005 and remain at that level thereafter. The health care cost trend rate
assumption has a significant effect on the amounts reported. To illustrate,
increasing assumed health care cost by 1% in each year would increase the
accumulated postretirement benefit obligation as of July 31, 1996 by $218,000
and the aggregate of the service and interest cost components of net periodic
postretirement benefit cost by $33,000 for the year ended July 31, 1996. The
weighted average discount rate used in determining the accumulated
postretirement benefit obligation was 8%.
11. COMMITMENTS AND CONTINGENCIES
LEASES
The Company has various commitments under capital and operating leases through
2009 relating to computer hardware and software, its pharmaceutical
manufacturing facility and warehouses in St. Louis, Missouri, its facility in
the United Kingdom and administrative offices in Rockville, Maryland and St.
Louis, Missouri.
Future minimum rentals as of July 31, 1996 under noncancellable leases are as
follows:
Capital Operating
Year Ending July 31 Leases Leases
------------------- ------ -------
1997 $118,300 $ 947,500
1998 19,200 923,600
1999 875,200
2000 798,700
2001 653,800
Thereafter 1,659,600
--------- -----------
137,500 $ 5,858,400
-----------
-----------
Less amount representing
interest (imputed at 10.5%) (20,400)
--------
Capital lease obligations 117,100
Less current portion 99,800
--------
Long-term obligations $ 17,300
--------
--------
40
These future minimum rentals do not include CPI adjustments to which some of the
leases are subject. The Company incurred rental expense of $818,800 in 1996,
$773,400 in 1995 and $728,300 in 1994. During fiscal 1996 and 1995, the Company
amortized $30,200 of lease incentives previously deferred in fiscal 1994 and
prior (aggregating $226,600) which were received in connection with a lease for
office space. These incentives are being amortized over the ten-year life of
the respective lease. The schedule of operating lease payments does not include
reimbursement of rent expense related to the sublease agreement for the
corporate office facility discussed in Note 3 of the Notes to Consolidated
Financial Statements.
SALE/LEASEBACK OF CORPORATE HEADQUARTERS BUILDING
In connection with the December 1988 sale of the Company's former corporate
headquarters building in Bethesda, Maryland, the Company's obligations under the
Leasehold Deed of Trust ("Ground Lease") were assigned to and assumed by the
purchaser of the building. The Company remains contingently liable under the
Ground Lease. The annual commitment under the Ground Lease aggregated $143,700
in 1996 (adjusted for increases in the Consumer Price Index) and extends until
the year 2042.
LITIGATION
Lawsuits and claims are filed from time to time against the Company and its
subsidiaries in the ordinary course of business. Management of the Company,
after reviewing developments to date with legal counsel, is of the opinion that
the outcome of such matters will not have a material adverse effect on the
consolidated financial position or results of operations of the Company.
GOVERNMENT CONTRACT REVENUE
The Company's supply contracts with the Department of Defense ("DoD") are
subject to post-award audit and potential price redetermination. In the opinion
of management, adjustments, if any, on completed contracts would not have a
material adverse effect on the Company's consolidated financial position or
results of operations.
EMPLOYEE CONTRACTS
The Company entered into agreements with certain key employees which provide for
certain benefits should the employee be terminated within the term of the
agreement for other than specified reasons. The Company also entered into
agreements with certain other key employees which provide for certain benefits
should the employee be terminated within a two year period subsequent to a
change of control (as defined by the agreements) for other than specified
reasons. Benefits to be provided under these agreements include continued life,
disability, accident and health insurance coverage for a period of two years and
a severance payment up to 200% of the employee's annual base compensation.
Additionally, all stock options held by the employee become immediately
exercisable and any restrictions on transfer of the Company's stock held by the
employee shall lapse. These agreements began to expire in April 1996 through
December 1996 and renew for one-year periods unless timely notice of non-renewal
is given. The maximum contingent liability under these agreements at July 31,
1996 aggregates $1.3 million.
41
12. CASH FLOWS
During fiscal 1995 and 1994, the Company entered into additional capital leases
for more computer hardware related to the new management information system
totalling $170,400 and $104,900 respectively. There was no such activity in
fiscal 1996.
13. INDUSTRY SEGMENT INFORMATION
The Company has no significant foreign operations and operates in one industry
segment which includes the design, development, manufacture and sale of medical
products and related services, with a major focus on safe and convenient
participation by the patient in injection therapy.
Financial information relating to major customers and export sales follows:
Year Ended July 31 1996 1995 1994
- ------------------ ----------- ----------- -----------
Sales to major U.S. customers:
U.S. Department of Defense $14,299,000 $ 7,439,500 $ 5,669,000
Center Laboratories, Inc. 11,171,900 9,756,700 8,325,200
Bristol-Myers Squibb 865,800 1,592,700 3,042,000
Development Contracts 2,282,200 2,264,700 2,862,700
Other 918,800 1,237,500 2,172,200
----------- ----------- -----------
29,537,800 22,291,100 22,071,100
----------- ----------- -----------
Export sales:
Contract Sales to the
Governments of Foreign
Countries 1,675,100 3,050,400 1,427,700
Other 172,400 145,300 1,357,700
----------- ----------- -----------
Total net sales $31,385,200 $25,486,800 $24,856,500
----------- ----------- -----------
----------- ----------- -----------
Substantially all export revenue consists of sales of automatic injectors to
the Government of Israel and sales of medical devices, primarily
CardioBeepers, to a company in Israel during fiscal year 1994. The Company
extends credit to domestic customers and generally requires a letter of
credit for export sales.
14. OTHER LIABILITIES AND ACCRUED EXPENSES
Included in other liabilities and accrued expenses at July 31, 1996 and 1995 are
costs related to accrued employee compensation totalling $415,900 and $444,100
respectively.
15. RELATED PARTY TRANSACTIONS
On April 15, 1996, Brunswick Biomedical Corporation ("BBC"), a privately held
medical device company acquired 61.1% of the Company's outstanding stock.
During the current year, the Company provided office space and certain
administrative services to BBC at fair values which totalled $8,700 and were
outstanding and unpaid at July 31, 1996. The Company also has an additional
balance of $168,700 for costs incurred on behalf of BBC included in receivables
which too is outstanding and unpaid as of July 31, 1996.
42
16. QUARTERLY OPERATING RESULTS (UNAUDITED)
(IN THOUSANDS, EXCEPT PER SHARE DATA)
Quarter Ended
----------------------------------------------------
FISCAL YEAR 1996 Oct 31 Jan 31 Apr 30 Jul 31
- ---------------- ------- ------- ------- -------
Net sales $ 5,295 $ 8,569 $ 8,897 $ 8,624
Cost of sales 3,515 6,187 6,731 5,995
------- ------- ------- -------
Gross profit 1,780 2,382 2,166 2,629
Operating expenses (1) 1,491 1,629 1,516 2,047
------- ------- ------- -------
Operating income 289 753 650 582
Other (expense) income, net (54) (139) (71) (35)
------- ------- ------- -------
Income before income taxes 235 614 579 547
Provision for income taxes 91 232 220 156
------- ------- ------- -------
Net income $ 144 $ 382 $ 359 $ 391
------- ------- ------- -------
------- ------- ------- -------
Net income per share $ .05 $ .12 $ .12 $ .12
------- ------- ------- -------
------- ------- ------- -------
FISCAL YEAR 1995 Oct 31 Jan 31 Apr 30 Jul 31
- ---------------- ------- ------- ------- -------
Net sales $ 4,967 $ 6,445 $ 5,592 $ 8,483
Cost of sales 3,216 4,671 3,693 5,648
------- ------- ------- -------
Gross profit 1,751 1,774 1,899 2,835
Operating expenses (1) 1,677 1,696 1,616 2,380
------- ------- ------- -------
Operating income 74 78 283 455
Other (expense) income, net (33) (41) (44) (62)
------- ------- ------- -------
Income before income taxes 41 37 239 393
Provision for income taxes 16 13 85 136
------- ------- ------- -------
Net income $ 25 $ 24 $ 154 $ 257
------- ------- ------- -------
------- ------- ------- -------
Net income per share $ .01 $ .01 $ .05 $ .08
------- ------- ------- -------
------- ------- ------- -------
(1) During the quarters ended July 31, 1996, October 31, 1995 and July 31, 1995,
the Company recorded a restructuring charge of $227,800, $94,100 and $450,000,
respectively, which increased operating expenses accordingly.
43
ITEM 8. CONTINUED:
REPORT OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and Shareholders
Survival Technology, Inc.
In our opinion, the consolidated financial statements listed in the index
appearing under Item 14(a) (1) and (2) on pages 44 and 45 present fairly, in all
material respects, the financial position of Survival Technology, Inc. and its
subsidiaries at July 31, 1996 and 1995, and the results of their operations and
their cash flows for each of the three years in the period ended July 31, 1996,
in conformity with generally accepted accounting principles. These financial
statements are the responsibility of the Company's management; our
responsibility is to express an opinion on these financial statements based on
our audits. We conducted our audits of these statements in accordance with
generally accepted auditing standards which require that we plan and perform the
audit to obtain reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements,
assessing the accounting principles used and significant estimates made by
management, and evaluating the overall financial statement presentation. We
believe that our audits provide a reasonable basis for the opinion expressed
above.
PRICE WATERHOUSE LLP
Washington, DC
October 3, 1996
44
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE
The Company has never filed a Current Report on Form 8-K reporting a change of
accountants because of a disagreement on any matter of accounting principles or
practices or financial statement disclosure or otherwise.
PART III
ITEMS 10. THROUGH 13.
Information required by Part III (Items 10 through 13) of this Form 10-K is
incorporated by reference to the Company's definitive Proxy Statement for the
Annual Meeting of Shareholders for the fiscal year ended July 31, 1996, which
will be filed with the Securities and Exchange Commission not later than 120
days after the end of the fiscal year to which this report relates.
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS
FORM 8-K
(a) The following documents are filed with or incorporated
by reference as part of this report:
1. Financial Statements:
Consolidated Balance Sheets at July 31, 1996 and July 31, 1995
Consolidated Statements of Income for the years ended July 31, 1996,
July 31, 1995 and July 31, 1994.
Consolidated Statements of Shareholders' Equity for the years ended
July 31, 1996, July 31, 1995 and July 31, 1994.
Consolidated Statements of Cash Flows for the years ended July 31,
1996, July 31, 1995 and July 31, 1994.
Notes to Consolidated Financial Statements
Report of Independent Accountants
The above-listed financial statements are included in Item 8 to this Form
10-K.
45
2. Financial Statement Schedules:
The following financial statement schedules immediately follow the
signatures to this report:
Schedule V - Property and Equipment
Schedule VI - Accumulated Depreciation and Amortization of
Property and Equipment
Schedule VIII - Valuation and Qualifying Accounts and Reserves
All other schedules are omitted because they are immaterial, not
applicable or the required information is shown in the
consolidated financial statements or the notes thereto.
3. Exhibits:
Exhibit No. Description of Exhibit
- ----------- ----------------------
(2.1) Asset Purchase Agreement dated July 31, 1994 between Survival
Technology, Inc. and Brunswick Biomedical Corporation.
Incorporated by reference to Exhibit (2.1) to the Company's
Annual Report on Form 10-K for the year ended July 31, 1994 (File
No. 0-5958).
(2.2) Agreement and Plan of Merger dated September 11, 1996 between
SurvivalTechnology, Inc. and Brunswick Biomedical Corporation.
Incorporated byreference to Exhibit 6(a) to amendment No. 1 to
Schedule 13D filed by Brunswick Biomedical Corporation dated
September 13, 1996.
(3.1) The Company's Bylaws (As Amended). Filed herewith.
(3.2) The Company's Articles of Incorporation (As Amended).
Incorporated by reference to Exhibit (3.2) to the Company's
Annual Report on Form 10-K for the year ended July 31, 1987 (File
No. 0-5958).
(10.1) Indenture of Lease, dated January 1, 1982, between Survival
Technology, Inc. and Abraham M. Morrison. Incorporated by
reference to Exhibit (10.1) to the Company's Annual Report on
Form 10-K for the year ended July 31, 1988 (File No. 0-5958).
(10.2) Revolving Credit Agreement dated November 4, 1993 between Merrill
Lynch Financial Business Services, Inc. and the Company.
Incorporated by reference to Exhibit (10.2) to the Company's
Annual Report on Form 10-K for the year ended July 31, 1994.
(10.2.1) Revolving Credit Extension Agreement dated August 15, 1996
between Merrill Lynch Financial Business Services, Inc. and the
Company. Filed herewith.
46
(10.3.1) Registration Rights Agreement dated September 14, 1990 made by
the Company in favor of Robert E. Herzstein as Personal
Representative of the Estate of Stanley J. Sarnoff. Incorporated
by reference to Exhibit (10.2.3) to the Company's Annual Report
on Form 10-K for the year ended July 31, 1990 (File No. 0-5958).
(10.3.2) Option Agreement dated September 14, 1990 made by the Company in
favor of Robert E. Herzstein as Personal Representative of the
Estate of Stanley J. Sarnoff. Incorporated by reference to
Exhibit (10.2.2) to the Company's Annual Report and Form 10-K for
the year ended July 31, 1990 (File No. 0-5958).
(10.3.3) Option Agreement Amendment dated September 14, 1993 made by the
Company in favor of Robert E. Herzstein as Personal
Representative of the Estate of Stanley J. Sarnoff. Incorporated
by reference to Exhibit (10.3.3) to the Company's Annual Report
and Form 10-K for the year ended July 31, 1994 (File No. 0-5958).
(10.4) Survival Technology, Inc., 1982 Stock Option Plan. Incorporated
by reference to Exhibit (4.4) to Registration Statement No. 2-
80908 on Form S-8. *
(10.5) Survival Technology, Inc. 1986 Stock Option Plan (As Amended).
Incorporated by reference to Exhibit (4.2) to Registration
Statement No. 33-46981 on Form S-8. *
(10.6) Contract SP0200-96-D-0001 dated October 27, 1995 between the U.
S. Government (Defense Personnel Support Center) and the Company.
Filed herewith (File No. 0-5958)
(10.6.1) Contract SP0200-96-D-0001 modification No. 8004 dated October 15,
1996 between the U.S. Government (Defense Personnel Support
Center) and the Company. Filed herewith (File No. 0-5958).
(10.7) Agreement dated as of January 1, 1987 between Center
Laboratories, a division of EM Industries, Inc. and the Company.
Incorporated by reference to Exhibit (10.11) to the Company's
Annual Report on Form 10-K for the year ended July 31, 1988 (File
No. 0-5958).
(10.7.1) Letter Agreement dated as of January 31, 1990 between Center
Laboratories, a division of EM Industries, Inc. and the Company.
Incorporated by reference to Exhibit (10.10.1) to the Company's
Annual Report on Form 10-K for the year ended July 31, 1990.
(10.8) Agreement dated June 23, 1981 between Survival Technology, Inc.
and American Home Products Corporation. Incorporated by
reference to Exhibit (10.12) to the Company's Annual Report on
Form 10-K for the year ended July 31, 1988 (File No. 0-5958).
47
(10.8.1) License Agreement dated April 20, 1982 between Survival
Technology, Inc. and American Home Products Corporation.
Incorporated by reference to Exhibit (10.12.1) to the Company's
Annual Report on Form 10-K for the year ended July 31, 1988 (File
No. 0-5958).
(10.8.2) Supply Agreement dated August 3, 1993 between Survival
Technology, Inc. and Wyeth-Ayerst Laboratories (A Division of
American Home Products Corporation). Incorporated by reference
to Exhibit (10.7.2) to the Company's Annual Report on Form 10-K
for the year ended July 31, 1993 (File No. 0-5958).
(10.9) Loan Agreement dated April 16, 1991 between Syntex Laboratories,
Inc. and the Company. Incorporated by reference to Exhibit
(10.11.1) to the Company's Current Report on Form 8-K dated April
16, 1991 (File No. 0-5958).
(10.9.1) Agreement dated November 25, 1993 between Survival Technology,
Inc. and Syntex Laboratories, Inc. with respect to the
termination of the March 1, 1989 Manufacturing and Packaging
Agreement. Incorporated by reference to Exhibit (10.9.2) to the
Company's Annual Report on Form 10-K for the year ended July 31,
1993.
(10.10) Development, Manufacturing and Supply Agreement between Mylan
Laboratories, Inc. and Survival Technology, Inc. dated August 31,
1993. Incorporated by reference to Exhibit (10.11) to the
Company's Annual Report on Form 10-K for the year ended July 31,
1993 (File No. 0-5958).
(10.10.1) Development, Manufacturing and Supply Amendment Agreement dated
July 28, 1994 between Mylan Laboratories,Inc. and Survival
Technology, Inc. Incorporated by reference to Exhibit (10.12.1)
to the Company's Annual Report on Form 10-K for the year ended
July 31, 1994.
(10.11) Lease Agreement dated August 26, 1991 between Pru Beta 2 and the
Company. Incorporated by reference to Exhibit (10.12) to the
Company's Annual Report on Form 10-K for the year ended July 31,
1991 (File No. 0-5958).
(10.12) Employment Agreement dated March 2, 1993 between James H. Miller
and the Company. Incorporated by reference to Exhibit (10.13) to
the Company's Annual Report on Form 10-K for the year ended
July 31, 1993 (File No. 0-5958). *
(10.12.1) Employment Agreement dated January 28, 1994 between Jeffrey W.
Church and the Company. Incorporated by reference to Exhibit
(10.14.1) to the Company's Annual Report on Form 10-K for the
year ended July 31, 1994. (File No. 0-5958). *
(10.12.2) Employment Agreement dated January 28, 1994 between Glenn F.
Wickes and the Company. Incorporated by reference to Exhibit
(10.14.2) to the Company's Annual Report on Form 10-K for the
year ended July 31, 1994 (File No. 0-5958). *
48
(10.12.3) Change in Control Agreement dated January 10, 1996 between Mark
D. Ruby and the Company. Filed herewith. *
(10.13) Commitment letter dated May 4, 1995 between The CIT Group/
Equipment Financing, Inc. and the Company. Incorporated by
reference to Exhibit (10.15) to the Company's Annual Report on
Form 10-K for the year ended July 31, 1995 (File No. 0-5958).
(10.14) Letter dated March 15, 1996 from Brunswick Biomedical
Corporation. Incorporated by reference to Exhibit (10) to Form
8-K dated March 19, 1996.
(22) A list of the Company's subsidiaries is not provided because
they, considered in the aggregate as a single subsidiary, would
not constitute a significant subsidiary as of the end of the year
covered by this report.
(24) Consent of Independent Accountants. Filed herewith.
* Management contract, compensatory plan or arrangement.
(b) Reports on Form 8-K:
There were no Current Reports on Form 8-K filed by the Registrant
during the three months ended July 31, 1996.
49
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
SURVIVAL TECHNOLOGY, INC.
-------------------------
(Registrant)
By /S/JAMES H. MILLER
---------------------
James H. Miller
Chairman of the Board
President & CEO
Dated: October 22, 1996
Pursuant to the requirements of the Securities Exchange Act of 1934, this report
has been signed below by the following persons on behalf of the Registrant and
in the capacities and on the dates indicated:
/S/JAMES H. MILLER Chairman of the Board October 22, 1996
- ------------------ President and Director
James H. Miller (Principal Executive Officer)
/S/JEFFREY W. CHURCH Senior Vice President, Finance October 22, 1996
- -------------------- (Principal Financial and
Jeffrey W. Church Accounting Officer)
/S/BRUCE M. DRESNER Director October 22, 1996
- -------------------
Bruce M. Dresner
/S/ROBERT G. FOSTER Director October 22, 1996
- -------------------
Robert G. Foster
/S/DAVID L. LOUGEE Director October 22, 1996
- ------------------
David L. Lougee
/S/E. ANDREWS GRINSTEAD, III Director October 22, 1996
- ----------------------------
E. Andrews Grinstead, III
50
FINANCIAL STATEMENT SCHEDULES
SCHEDULE V
SURVIVAL TECHNOLOGY, INC.
PROPERTY AND EQUIPMENT
Balance at Balance at
Beginning Additions at End
Classification of Period at Cost Retirements Dispositions Transfers of Period
- -------------- --------- --------- ----------- ------------ --------- ----------
For the year ended
July 31, 1994
- ------------------
Furniture and equipment $12,252,800 $ 515,600 $ $ (274,600)(1) $1,629,800 $14,123,600
Leasehold improvements 2,766,900 70,600 563,300 3,400,800
Construction in progress 3,001,800 2,586,600 (2,193,100) 3,395,300
----------- ---------- --------- ---------- ---------- -----------
$18,021,500 $3,172,800 $ -0- $ (274,600) $ -0- $20,919,700
----------- ---------- --------- ---------- ---------- -----------
----------- ---------- --------- ---------- ---------- -----------
For the year ended
July 31, 1995
- ------------------
Furniture and equipment $14,123,600 $ 512,500 $ $ (136,200) $ 889,100 $15,389,000
Leasehold improvements 3,400,800 5,700 2,213,300 5,619,800
Construction in progress 3,395,300 3,279,600 (3,102,400) 3,572,500
----------- ---------- --------- ---------- ---------- -----------
$20,919,700 $3,797,800 $ -0- $ (136,200) $ -0- $24,581,300
----------- ---------- --------- ---------- ---------- -----------
----------- ---------- --------- ---------- ---------- -----------
For the year ended
July 31, 1996
- -------------------
Furniture and equipment $15,389,000 $ 43,500 $ $ (371,900) $2,635,900 $17,696,500
Leasehold improvements 5,619,800 1,107,000 6,726,800
Construction in progress 3,572,500 2,294,500 (3,742,900) 2,124,100
----------- ---------- --------- ---------- ---------- -----------
$24,581,300 $2,338,000 $ -0- $ (371,900) $ -0- $26,547,400
----------- ---------- --------- ---------- ---------- -----------
----------- ---------- --------- ---------- ---------- -----------
(1) Includes $94,100 of Medical Device equipment sold to Brunswick Biomedical
Corporation
51
SCHEDULE VI
SURVIVAL TECHNOLOGY, INC.
ACCUMULATED DEPRECIATION AND AMORTIZATION
OF PROPERTY AND EQUIPMENT
Additions
Balance at Charged to Balance
Beginning Cost and at End
Classification of Period Expenses Retirements Dispositions of Period
- -------------- ---------- --------- ----------- ----------- ---------
For the year ended
July 31, 1994
- ------------------
Furniture and equipment $5,976,700 $ 819,300 $ $ (171,500) $ 6,624,500
Leasehold improvements 2,244,000 158,500 2,402,500
----------- ---------- ----------- ------------ -----------
$8,220,700 $ 977,800 $ -0- $ (171,500) $ 9,027,000
----------- ---------- ----------- ------------ -----------
----------- ---------- ----------- ------------ -----------
For the year ended
July 31, 1995
- ------------------
Furniture and equipment $6,624,500 $1,228,000 $ $ (136,200) $ 7,716,300
Leasehold improvements 2,402,500 253,600 2,656,100
----------- ---------- ----------- ------------ -----------
$9,027,000 $1,481,600 $ -0- $ (136,200) $10,372,400
----------- ---------- ----------- ------------ -----------
----------- ---------- ----------- ------------ -----------
For the year ended
July 31, 1996
- ------------------
Furniture and equipment $ 7,716,300 $1,405,400 $ $ (332,300) $ 8,789,400
Leasehold improvements 2,656,100 286,900 2,943,000
----------- ---------- ----------- ------------ -----------
$10,372,400 $1,692,300 $ $ (332,300) $11,732,400
----------- ---------- ----------- ------------ -----------
----------- ---------- ----------- ------------ -----------
52
SCHEDULE VIII
SURVIVAL TECHNOLOGY, INC.
VALUATION AND QUALIFYING ACCOUNTS AND RESERVES
Additions
Balance at Charged to Balance
Beginning Costs and Write-off at End
of Period Expenses Deductions of Period
---------- ---------- ---------- ---------
For the year ended
July 31, 1994
- ------------------
Allowance for doubtful accounts $ 177,500 $ 31,100 $ 178,600 $ 30,000
---------- ---------- ----------- ----------
---------- ---------- ----------- ----------
Inventory reserves $ 235,900 $ 82,000 $ 40,100 $ 277,800
---------- ---------- ----------- ----------
---------- ---------- ----------- ----------
For the year ended
July 31, 1995
- ------------------
Allowance for doubtful accounts $ 30,000 $ 144,300 $ 161,300 $ 13,000
---------- ---------- ----------- ----------
---------- ---------- ----------- ----------
Inventory reserves $ 277,800 $ 308,400 $ 355,900 $ 230,300
---------- ---------- ----------- ----------
---------- ---------- ----------- ----------
For the year ended
July 31, 1996
- ------------------
Allowance for doubtful accounts $ 13,000 $ 48,600 $ 16,600 $ 45,000
---------- ---------- ----------- ----------
---------- ---------- ----------- ----------
Inventory reserves $ 230,300 $ 297,900 $ 90,700 $ 437,500
---------- ---------- ----------- ----------
---------- ---------- ----------- ----------
SURVIVAL TECHNOLOGY, INC.
EXHIBIT INDEX
FORM 10-K
FOR THE FISCAL YEAR ENDED JULY 31, 1995
Exhibit No. Description of Exhibit
- ----------- ----------------------
(2.1) Asset Purchase Agreement dated July 31, 1994 between Survival
Technology, Inc. and Brunswick Biomedical Corporation.
Incorporated by reference to Exhibit (2.1) to the Company's
Annual Report on Form 10-K for the year ended July 31, 1994 (File
No. 0-5958).
(2.2) Agreement and Plan of Merger dated September 11, 1996 between
Survival Technology, Inc. and Brunswick Biomedical Corporation.
Incorporated by reference to Exhibit 6(a) to amendment No. 1 to
Schedule 13D filed by Brunswick Biomedical Corporation dated
September 13, 1996.
(3.1) The Company's Bylaws (As Amended). Filed herewith.
(3.2) The Company's Articles of Incorporation (As Amended).
Incorporated by reference to Exhibit (3.2) to the Company's
Annual Report on Form 10-K for the year ended July 31, 1987 (File
No. 0-5958).
(10.1) Indenture of Lease, dated January 1, 1982, between Survival
Technology, Inc. and Abraham M. Morrison. Incorporated by
reference to Exhibit (10.1) to the Company's Annual Report on
Form 10-K for the year ended July 31, 1988 (File No. 0-5958).
(10.2) Revolving Credit Agreement dated November 4, 1993 between Merrill
Lynch Financial Business Services, Inc. and the Company.
Incorporated by reference to Exhibit (10.2) to the Company's
Annual Report on Form 10-K for the year ended July 31, 1994.
(10.2.1) Revolving Credit Extension Agreement dated August 15, 1996
between Merrill Lynch Financial Business Services, Inc. and the
Company. Filed herewith.
(10.3.1) Registration Rights Agreement dated September 14, 1990 made by
the Company in favor of Robert E. Herzstein as Personal
Representative of the Estate of Stanley J. Sarnoff. Incorporated
by reference to Exhibit (10.2.3) to the Company's Annual Report
on Form 10-K for the year ended July 31, 1990 (File No. 0-5958).
(10.3.2) Option Agreement dated September 14, 1990 made by the Company in
favor of Robert E. Herzstein as Personal Representative of the
Estate of Stanley J. Sarnoff. Incorporated by reference to
Exhibit (10.2.2) to the Company's Annual Report and Form 10-K for
the year ended July 31, 1990 (File No. 0-5958).
(10.3.3) Option Agreement Amendment dated September 14, 1993 made by the
Company in favor of Robert E. Herzstein as Personal
Representative of the Estate of Stanley J. Sarnoff. Incorporated
by reference to Exhibit (10.3.3) to the Company's Annual Report
and Form 10-K for the year ended July 31, 1994 (File No. 0-5958).
54
(10.4) Survival Technology, Inc., 1982 Stock Option Plan. Incorporated
by reference to Exhibit (4.4) to Registration Statement No. 2-
80908 on Form S-8. *
(10.5) Survival Technology, Inc. 1986 Stock Option Plan (As Amended).
Incorporated by reference to Exhibit (4.2) to Registration
Statement No. 33-46981 on Form S-8. *
(10.6) Contract SP0200-96-D-0001 dated October 27, 1995 between the U.
S. Government (Defense Personnel Support Center) and the Company.
Filed herewith (File No. 0-5958)
(10.6.1) Contract SP0200-96-D-0001 modification No. 8004 dated October 15,
1996 between the U.S. Government (Defense Personnel Support
Center) and the Company. Filed herewith (File No. 0-5958).
(10.7) Agreement dated as of January 1, 1987 between Center
Laboratories, a division of EM Industries, Inc. and the Company.
Incorporated by reference to Exhibit (10.11) to the Company's
Annual Report on Form 10-K for the year ended July 31, 1988 (File
No. 0-5958).
(10.7.1) Letter Agreement dated as of January 31, 1990 between Center
Laboratories, a division of EM Industries, Inc. and the Company.
Incorporated by reference to Exhibit (10.10.1) to the Company's
Annual Report on Form 10-K for the year ended July 31, 1990.
(10.8) Agreement dated June 23, 1981 between Survival Technology, Inc.
and American Home Products Corporation. Incorporated by
reference to Exhibit (10.12) to the Company's Annual Report on
Form 10-K for the year ended July 31, 1988 (File No. 0-5958).
(10.8.1) License Agreement dated April 20, 1982 between Survival
Technology, Inc. and American Home Products Corporation.
Incorporated by reference to Exhibit (10.12.1) to the Company's
Annual Report on Form 10-K for the year ended July 31, 1988 (File
No. 0-5958).
(10.8.2) Supply Agreement dated August 3, 1993 between Survival
Technology, Inc. and Wyeth-Ayerst Laboratories (A Division of
American Home Products Corporation). Incorporated by reference
to Exhibit (10.7.2) to the Company's Annual Report on Form 10-K
for the year ended July 31, 1993 (File No. 0-5958).
(10.9) Loan Agreement dated April 16, 1991 between Syntex Laboratories,
Inc. and the Company. Incorporated by reference to Exhibit
(10.11.1) to the Company's Current Report on Form 8-K dated
April 16, 1991 (File No. 0-5958).
(10.9.1) Agreement dated November 25, 1993 between Survival Technology,
Inc. and Syntex Laboratories, Inc. with respect to the
termination of the March 1, 1989 Manufacturing and Packaging
Agreement. Incorporated by reference to Exhibit (10.9.2) to the
Company's Annual Report on Form 10-K for the year ended July 31,
1993.
55
(10.10) Development, Manufacturing and Supply Agreement between Mylan
Laboratories, Inc. and Survival Technology, Inc. dated August 31,
1993. Incorporated by reference to Exhibit (10.11) to the
Company's Annual Report on Form 10-K for the year ended July 31,
1993 (File No. 0-5958).
(10.10.1) Development, Manufacturing and Supply Amendment Agreement dated
July 28, 1994 between Mylan Laboratories,Inc. and Survival
Technology, Inc. Incorporated by reference to Exhibit (10.12.1)
to the Company's Annual Report on Form 10-K for the year ended
July 31, 1994.
(10.11) Lease Agreement dated August 26, 1991 between Pru Beta 2 and the
Company. Incorporated by reference to Exhibit (10.12) to the
Company's Annual Report on Form 10-K for the year ended July 31,
1991 (File No. 0-5958).
(10.12) Employment Agreement dated March 2, 1993 between James H. Miller
and the Company. Incorporated by reference to Exhibit (10.13) to
the Company's Annual Report on Form 10-K for the year ended July
31, 1993 (File No. 0-5958). *
(10.12.1) Employment Agreement dated January 28, 1994 between Jeffrey W.
Church and the Company. Incorporated by reference to Exhibit
(10.14.1) to the Company's Annual Report on Form 10-K for the
year ended July 31, 1994. (File No. 0-5958). *
(10.12.2) Employment Agreement dated January 28, 1994 between Glenn F.
Wickes and the Company. Incorporated by reference to Exhibit
(10.14.2) to the Company's Annual Report on Form 10-K for the
year ended July 31, 1994 (File No. 0-5958). *
.
(10.12.3) Change in Control Agreement dated January 10, 1996 between Mark
D. Ruby and the Company. Filed herewith. *
(10.13) Commitment letter dated May 4, 1995 between The CIT Group/
Equipment Financing, Inc. and the Company. Incorporated by
reference to Exhibit (10.15) to the Company's Annual Report on
Form 10-K for the year ended July 31, 1995 (File No. 0-5958).
(10.14) Letter dated March 15, 1996 from Brunswick Biomedical
Corporation. Incorporated by reference to Exhibit (10) to Form
8-K dated March 19, 1996.
(22) A list of the Company's subsidiaries is not provided because
they, considered in the aggregate as a single subsidiary, would
not constitute a significant subsidiary as of the end of the year
covered by this report.
(24) Consent of Independent Accountants. Filed herewith.
* Management contract, compensatory plan or arrangement.
(b) Reports on Form 8-K:
There were no Current Reports on Form 8-K filed by the Registrant
during the three months ended July 31, 1996.